Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

MEDP

Medpace Holdings Inc

Oct 30 • 04:00PM ET

580.37

-4.20 -0.72 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: IQV CRL INCY LH ICON CTLT KOD FATE ALLO ONC

| Held by: IJH VTI VB XMHQ VBK VXF MDY IWP IBB IJK

Index	-	P/E	40.59	EPS (ttm)	14.30	Insider Own	19.12%	Shs Outstand	28.10M	Perf Week	-2.72%
Market Cap	16.35B	Forward P/E	35.10	EPS next Y	16.54	Insider Trans	-3.63%	Shs Float	22.78M	Perf Month	6.71%
Enterprise Value	16.21B	PEG	3.05	EPS next Q	4.18	Inst Own	95.30%	Short Float	7.36%	Perf Quarter	37.17%
Income	433.00M	P/S	6.93	EPS this Y	16.70%	Inst Trans	3.26%	Short Ratio	4.81	Perf Half Y	92.02%
Sales	2.36B	P/B	55.53	EPS next Y	12.19%	ROA	22.57%	Short Interest	1.68M	Perf YTD	74.69%
Book/sh	10.45	P/C	57.29	EPS next 5Y	13.32%	ROE	73.70%	52W High	625.00 -7.14%	Perf Year	76.22%
Cash/sh	10.13	P/FCF	24.16	EPS past 3/5Y	37.94% 36.50%	ROIC	104.92%	52W Low	250.05 132.10%	Perf 3Y	165.66%
Dividend Est.	-	EV/EBITDA	30.26	Sales past 3/5Y	22.68% 19.62%	Gross Margin	29.90%	Volatility	3.50% 3.63%	Perf 5Y	398.00%
Dividend TTM	-	EV/Sales	6.87	EPS Y/Y TTM	23.92%	Oper. Margin	21.50%	ATR (14)	20.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.57	Sales Y/Y TTM	13.88%	Profit Margin	18.36%	RSI (14)	64.50	Recom	3.54
Dividend Gr. 3/5Y	- -	Current Ratio	0.57	EPS Q/Q	28.34%	SMA20	6.16%	Beta	1.42	Target Price	538.40
Payout	0.00%	Debt/Eq	0.49	Sales Q/Q	23.74%	SMA50	13.21%	Rel Volume	0.60	Prev Close	584.57
Employees	5900	LT Debt/Eq	0.41	Earnings	Oct 22 AMC	SMA200	52.73%	Avg Volume	348.56K	Price	580.37
IPO	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.20% 2.95%	Trades		Volume	207,820	Change	-0.72%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-02-25	Downgrade	Barclays	Equal Weight → Underweight	$425
Sep-03-25	Downgrade	Rothschild & Co Redburn	Buy → Neutral	$474
Jul-29-25	Downgrade	UBS	Neutral → Sell	$305
Jul-23-25	Downgrade	TD Cowen	Hold → Sell	$366
Jun-24-25	Initiated	Barclays	Equal Weight	$300
Apr-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Apr-14-25	Downgrade	TD Cowen	Buy → Hold	$328
Mar-24-25	Initiated	Leerink Partners	Market Perform	$330
Oct-23-24	Downgrade	Robert W. Baird	Outperform → Neutral	$413 → $349
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-27-24	Downgrade	UBS	Buy → Neutral	$420 → $350
Sep-25-24	Downgrade	Jefferies	Buy → Hold	$415 → $345
Aug-01-24	Initiated	Truist	Hold	$415
May-29-24	Initiated	TD Cowen	Buy	$452
May-28-24	Initiated	Mizuho	Buy	$435
Apr-23-24	Upgrade	Jefferies	Hold → Buy	$340 → $450
Mar-18-24	Initiated	Deutsche Bank	Hold	$395
Feb-15-24	Upgrade	UBS	Neutral → Buy	$282 → $452
Oct-24-23	Upgrade	Robert W. Baird	Neutral → Outperform	$270 → $289
May-08-23	Upgrade	Guggenheim	Neutral → Buy	$252

Show Previous Ratings

Oct-30-25 09:04AM	Bio-Rad's Q3 Earnings Miss Estimates, Revenues Surpass, Stock Falls (Zacks)
Oct-29-25 09:40AM	Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:00AM	CVS Stock Falls Despite Q3 Earnings & Revenue Beat, '25 EPS View Up (Zacks)
01:35AM	5 Revealing Analyst Questions From Medpace's Q3 Earnings Call (StockStory)
Oct-28-25 12:00PM	Medpace (MEDP) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:12AM	Loading…
07:12AM	Best Momentum Stock to Buy for Oct. 28th (Zacks)
05:51AM	New Strong Buy Stocks for Oct. 28: NCNO, VRT, and More (Zacks)
Oct-27-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-24-25 06:06PM	Analyst Report: Medpace Holdings, Inc. (Morningstar Research)
01:05PM	Why Medpace Popped 13% This Week (Motley Fool)
Oct-23-25 04:11PM	Medpace Jumps On 'Another Strong Q' That Includes A Guidance Hike (Investor's Business Daily) +9.12%
03:07PM	Medpace Holdings Inc (MEDP) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Robust ... (GuruFocus.com)
02:06PM	MEDP Q3 Deep Dive: Broad-Based Growth and Strong Pipeline Fuel Upbeat Outlook (StockStory)
11:15AM	Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back (Barrons.com)
10:06AM	Biggest Market Mover Thursday: Medpace Stock Jumps On Strong Q3 Results (GuruFocus.com)
09:59AM	Loading…
09:59AM	Medpace Rockets On 'Another Strong Q' That Includes A Guidance Hike (Investor's Business Daily)
06:17AM	Stocks Muted Before the Open With Earnings in Focus (Barchart)
Oct-22-25 05:40PM	Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates (Zacks)
05:23PM	Medpace shares soar on blowout Q3 results, solid 2025 outlook (Investing.com)
05:03PM	Medpace (NASDAQ:MEDP) Beats Q3 Sales Expectations, Stock Jumps 18.5% (StockStory)
04:43PM	Medpace: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Medpace Holdings, Inc. Reports Third Quarter 2025 Results (Business Wire)
02:35PM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
11:40AM	SOLV or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
Oct-20-25 11:08PM	Medpace (MEDP) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-17-25 10:18AM	Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? (Zacks)
Oct-16-25 06:15PM	Medpace (MEDP) Rises As Market Takes a Dip: Key Facts (Zacks)
08:19AM	Should You be Excited about Medpace Holdings' (MEDP) Prospects? (Insider Monkey)
Oct-15-25 10:00AM	Medpace (MEDP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-14-25 09:57AM	Robust Booking Growth Boosted Medpace Holdings (MEDP) in Q3 (Insider Monkey)
06:15PM	Loading…
Oct-10-25 06:15PM	Medpace (MEDP) Dips More Than Broader Market: What You Should Know (Zacks) +5.22%
03:50PM	Medpace and Revvity Stocks Trade Down, What You Need To Know (StockStory)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Oct-09-25 12:10PM	Will Medpace (MEDP) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:48AM	Brookdale Posts Strong YoY Rise in September 2025 Occupancy (Zacks)
09:40AM	Is Medpace (MEDP) Outperforming Other Medical Stocks This Year? (Zacks)
08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Oct-07-25 12:30PM	Nyxoah Shares Rise on First U.S. Commercial Use of Genio System (Zacks)
Oct-06-25 10:16AM	ICCM Shares Rise as FDA Clears ProSense for Breast Cancer Treatment (Zacks)
Oct-05-25 11:32PM	Drug Development Inputs & Services Stocks Q2 Recap: Benchmarking Medpace (NASDAQ:MEDP) (StockStory)
Oct-03-25 11:40AM	SOLV vs. MEDP: Which Stock Is the Better Value Option? (Zacks)
Oct-02-25 06:15PM	Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors (Zacks)
11:36AM	Why Medpace (MEDP) Stock Is Trading Lower Today (StockStory)
09:40AM	Nike upgraded, RH downgraded: Wall Street's top analyst calls (The Fly)
09:34AM	Life science tools Q3 preview: Barclays ups Charles River, downgrades Medpace (Investing.com)
Sep-29-25 08:07AM	HTFL Gains FDA Clearance & Cigna Coverage for Next Gen Plaque Analysis (Zacks)
Sep-25-25 06:15PM	Medpace (MEDP) Dips More Than Broader Market: What You Should Know (Zacks)
12:54PM	TMDX Partners With Mercedes-Benz to Launch Organ Transport Network (Zacks)
Sep-23-25 04:05PM	Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025 (Business Wire)
01:15PM	STXS Stock Gains as Erasmus Medical Adopts Its Genesis Robotic System (Zacks)
01:11PM	Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now (Zacks)
Sep-22-25 12:33PM	Stryker Expands R&D Facility in India to Boost Medtech Innovation (Zacks)
12:27PM	Reasons to Hold AngioDynamics Stock in Your Portfolio for Now (Zacks)
09:46AM	Reasons to Retain Cooper Companies Stock in Your Portfolio for Now (Zacks)
09:09AM	Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus (Zacks)
Sep-19-25 09:19AM	Does Medpace Holdings (MEDP) Have a Long Runway For Growth? (Insider Monkey)
07:34AM	SGHT Shares Rise on Meta-Analysis Showing OMNI's Long-Term Benefits (Zacks)
Sep-18-25 10:14AM	Here's Why You Should Hold Accuray Stock in Your Portfolio for Now (Zacks)
10:05AM	SYK Partners With Siemens Healthineers to Boost Stroke, Aneurysm Care (Zacks)
08:42AM	Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio (Zacks)
08:41AM	Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy (Zacks)
Sep-17-25 10:41AM	BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care (Zacks)
08:51AM	CAH Strengthens Distribution With New Consumer Health Logistics Hub (Zacks)
08:50AM	GEHC Expands Women's Health Portfolio With AI-Enabled Voluson (Zacks)
Sep-16-25 11:40AM	SOLV or MEDP: Which Is the Better Value Stock Right Now? (Zacks)
10:26AM	ISRG Stock Dips Despite Introducing Real-Time Insights on da Vinci 5 (Zacks)
09:34AM	GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio (Zacks)
Sep-15-25 06:15PM	Why Medpace (MEDP) Outpaced the Stock Market Today (Zacks)
12:34PM	MMSI Stock Falls Despite CE Mark Win for Embosphere in Knee OA Care (Zacks)
Sep-12-25 03:49AM	The Zacks Analyst Blog Highlights Hasbro, Robinhood Markets, Interactive Brokers, Celsius and Medpace (Zacks)
Sep-11-25 12:24PM	Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study (Zacks)
12:20PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
09:45AM	5 Non-Tech Nasdaq Stocks to Buy That Helped the Index Surge in 2025 (Zacks)
08:24AM	Reasons to Add West Pharmaceutical Stock to Your Portfolio Now (Zacks)
Sep-10-25 12:35PM	Reasons to Retain Avanos Medical Stock in Your Portfolio Now (Zacks)
09:02AM	Dentsply Sirona Retains Wellspect Following Strategic Review (Zacks)
Sep-09-25 01:25PM	Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System (Zacks)
08:45AM	Lifeward Achieves European Approval for Latest ReWalk Exoskeleton (Zacks)
Sep-08-25 07:34PM	Medpace (MEDP) Outpaces Stock Market Gains: What You Should Know (Zacks)
12:36PM	Cardinal Health Expands At-Home Solutions With New Texas Facility (Zacks)
08:14AM	MYGN Stock Might Gain on The Lancet Study Backing Precise MRD (Zacks)
08:07AM	GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System (Zacks)
Sep-05-25 12:30PM	PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq (Zacks)
11:31AM	Medpace Holdings, Inc. (MEDP): A Bull Case Theory (Insider Monkey)
10:56AM	MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain? (Zacks)
08:06AM	Here's Why You Should Hold Cencora Stock in Your Portfolio Now (Zacks)
Sep-04-25 11:40AM	Here's Why You Should Retain Ecolab Stock in Your Portfolio Now (Zacks)
Sep-03-25 01:23PM	HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
08:50AM	STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep (Zacks)
Sep-02-25 01:32PM	IRTC Unveils Positive AMALFI Trial Data Showing Higher AF Detection (Zacks)
Sep-01-25 12:53PM	GEHC Launches AI-Powered Vivid Pioneer Cardiac Ultrasound System (Zacks)
09:54AM	ABT Stock Gains From Navitor's Expanded Indication Approval in Europe (Zacks)
09:51AM	FDA Identifies ICU Medical's Plum Duo Recall as Serious Type (Zacks)
Aug-29-25 12:24PM	Reasons to Retain TransMedics Stock in Your Portfolio for Now (Zacks)
09:47AM	Here's Why You Should Add CLOV Stock to Your Portfolio Now (Zacks)
09:47AM	COO Q3 Earnings Beat, 2025 Sales Outlook Lowered, Stock Down (Zacks)
Aug-28-25 11:40AM	COR vs. MEDP: Which Stock Is the Better Value Option? (Zacks)
10:24AM	VEEV Q2 Earnings & Revenues Beat Estimates, Margin Rises, Stock Up (Zacks)
08:14AM	PAHC Stock Surges on Q4 Earnings & Revenue Beat, Gross Margin Down (Zacks)
Aug-27-25 12:25PM	PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment (Zacks)

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVENPORT FRED B JR	Director	Oct 30 '25	Proposed Sale	581.88	5,972	3,474,993		Oct 30 10:38 AM
GEIGER JESSE J	President	Oct 27 '25	Option Exercise	166.73	19,460	3,244,566	55,963	Oct 29 05:12 PM
GEIGER JESSE J	President	Oct 29 '25	Option Exercise	166.73	3,568	594,893	40,071	Oct 29 05:12 PM
GEIGER JESSE J	President	Oct 27 '25	Sale	605.12	19,460	11,775,635	36,503	Oct 29 05:12 PM
GEIGER JESSE J	President	Oct 29 '25	Sale	585.00	3,568	2,087,280	36,503	Oct 29 05:12 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Oct 27 '25	Option Exercise	166.73	18,230	3,039,488	28,573	Oct 29 04:58 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Oct 27 '25	Sale	598.85	15,230	9,120,486	13,343	Oct 29 04:58 PM
BURWIG SUSAN E	Exec. VP, Operations	Oct 27 '25	Sale	605.01	2,000	1,210,020	65,500	Oct 29 04:52 PM
GEIGER JESSE J	Officer	Oct 29 '25	Proposed Sale	585.00	3,568	2,087,280		Oct 29 10:29 AM
GEIGER JESSE J	Officer	Oct 27 '25	Proposed Sale	605.12	19,460	11,775,659		Oct 27 04:08 PM
BURWIG SUSAN E	Officer	Oct 27 '25	Proposed Sale	605.01	2,000	1,210,016		Oct 27 04:07 PM
EWALD STEPHEN P	Officer	Oct 27 '25	Proposed Sale	598.85	15,230	9,120,538		Oct 27 10:30 AM
BURWIG SUSAN E	Exec. VP, Operations	Sep 26 '25	Option Exercise	107.93	10,000	1,079,300	67,500	Sep 30 04:15 PM
BURWIG SUSAN E	Exec. VP, Operations	Sep 03 '25	Sale	480.00	10,000	4,800,000	57,500	Sep 05 04:16 PM
BURWIG SUSAN E	Officer	Sep 03 '25	Proposed Sale	480.00	10,000	4,800,019		Sep 03 04:49 PM
Troendle August J.	CEO	Aug 29 '25	Sale	475.90	36,196	17,225,676	925,799	Sep 03 04:10 PM
Troendle August J.	CEO	Sep 02 '25	Sale	475.11	1,197	568,707	924,602	Sep 03 04:10 PM
Troendle August J.	CEO	Aug 27 '25	Sale	475.00	620	294,500	961,995	Aug 28 04:23 PM
BURWIG SUSAN E	Exec. VP, Operations	Aug 26 '25	Option Exercise	107.93	10,000	1,079,300	67,500	Aug 28 04:10 PM
August J. Troendle	Chairman	Aug 27 '25	Proposed Sale	475.00	38,013	18,056,018		Aug 27 05:09 PM
McCarthy Cornelius P. III	Director	Aug 19 '25	Sale	465.04	1,662	772,896	10,197	Aug 21 04:56 PM
McCarthy Cornelius P. III	Director	Aug 19 '25	Proposed Sale	465.04	1,662	772,894		Aug 19 03:00 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Jul 28 '25	Sale	450.00	3,000	1,350,000	10,343	Jul 29 06:02 PM
BURWIG SUSAN E	Exec. VP, Operations	Jul 28 '25	Sale	450.14	7,500	3,376,050	57,500	Jul 29 05:43 PM
Troendle August J.	CEO	Jul 28 '25	Sale	451.69	48,487	21,901,093	962,615	Jul 29 05:37 PM
GEIGER JESSE J	President	Jul 24 '25	Option Exercise	107.93	41,801	4,511,582	78,304	Jul 28 05:37 PM
GEIGER JESSE J	President	Jul 24 '25	Sale	453.11	41,801	18,940,451	36,503	Jul 28 05:37 PM
Brady Kevin M.	CFO & Treasurer	Jul 24 '25	Option Exercise	57.94	12,000	695,280	18,000	Jul 28 05:08 PM
Brady Kevin M.	CFO & Treasurer	Jul 24 '25	Sale	454.23	12,000	5,450,760	6,000	Jul 28 05:08 PM
BURWIG SUSAN E	Officer	Jul 28 '25	Proposed Sale	450.14	7,500	3,376,083		Jul 28 04:50 PM
August J. Troendle	Chairman	Jul 28 '25	Proposed Sale	451.68	356,446	161,001,311		Jul 28 04:35 PM
EWALD STEPHEN P	Officer	Jul 28 '25	Proposed Sale	450.00	3,000	1,350,000		Jul 28 03:27 PM
McCarthy Cornelius P. III	Director	Jul 22 '25	Option Exercise	54.99	1,972	108,440	11,859	Jul 24 04:31 PM
Brady Kevin M.	Officer	Jul 24 '25	Proposed Sale	454.23	12,000	5,450,751		Jul 24 04:13 PM
GEIGER JESSE J	Officer	Jul 24 '25	Proposed Sale	453.11	41,801	18,940,252		Jul 24 04:09 PM
McCarthy Cornelius P. III	Director	Jul 18 '25	Option Exercise	54.99	4,500	247,455	9,887	Jul 22 04:36 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Option Exercise	57.17	4,710	269,271	4,710	Apr 28 04:39 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Sale	301.82	1,712	516,716	2,998	Apr 28 04:39 PM
DAVENPORT FRED B JR	Director	Apr 24 '25	Proposed Sale	301.82	1,712	516,716		Apr 24 02:13 PM
Troendle August J.	CEO	Mar 07 '25	Option Exercise	68.62	356,446	24,458,835	1,011,102	Mar 10 05:47 PM
EWALD STEPHEN P	General Counsel & Corp. Secy.	Feb 27 '25	Buy	326.11	2	652	13,343	Feb 28 04:39 PM
Carley Brian T	Director	Feb 24 '25	Option Exercise	42.62	8,127	346,373	30,035	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Sale	345.59	4,003	1,383,397	26,032	Feb 26 04:18 PM
Carley Brian T	Director	Feb 24 '25	Proposed Sale	345.59	4,003	1,383,385		Feb 24 12:52 PM
GEIGER JESSE J	President	Dec 06 '24	Option Exercise	32.05	15,000	480,750	36,503	Dec 10 04:24 PM
BURWIG SUSAN E	Exec. VP, Operations	Nov 19 '24	Option Exercise	32.05	7,500	240,375	65,000	Nov 21 04:40 PM

Open in Screener

INCY

Incyte Corp

Oct 30 • 04:00PM ET

92.59

+2.41 2.67 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN GILD IONS BMY MRK JNJ AMGN PFE LLY

| Held by: VTI VOO VB VBK IVV SPY RSP USMV XBI IBB

Index	S&P 500	P/E	15.53	EPS (ttm)	5.96	Insider Own	1.21%	Shs Outstand	196.13M	Perf Week	3.67%
Market Cap	18.18B	Forward P/E	12.37	EPS next Y	7.48	Insider Trans	-2.35%	Shs Float	193.97M	Perf Month	6.79%
Enterprise Value	15.29B	PEG	0.15	EPS next Q	1.89	Inst Own	103.33%	Short Float	4.83%	Perf Quarter	22.49%
Income	1.19B	P/S	3.78	EPS this Y	513.70%	Inst Trans	1.84%	Short Ratio	4.87	Perf Half Y	49.27%
Sales	4.81B	P/B	3.90	EPS next Y	13.34%	ROA	20.96%	Short Interest	9.36M	Perf YTD	34.05%
Book/sh	23.71	P/C	6.20	EPS next 5Y	101.90%	ROE	30.39%	52W High	94.42 -1.94%	Perf Year	40.95%
Cash/sh	14.92	P/FCF	15.19	EPS past 3/5Y	-66.90% -40.36%	ROIC	25.39%	52W Low	53.56 72.87%	Perf 3Y	27.85%
Dividend Est.	-	EV/EBITDA	11.34	Sales past 3/5Y	12.41% 14.46%	Gross Margin	91.55%	Volatility	5.60% 3.50%	Perf 5Y	3.23%
Dividend TTM	-	EV/Sales	3.18	EPS Y/Y TTM	3563.21%	Oper. Margin	26.10%	ATR (14)	3.22	Perf 10Y	-15.07%
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	18.09%	Profit Margin	24.69%	RSI (14)	64.57	Recom	2.54
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	287.38%	SMA20	5.30%	Beta	0.74	Target Price	90.42
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	20.05%	SMA50	7.45%	Rel Volume	1.25	Prev Close	90.18
Employees	2617	LT Debt/Eq	0.01	Earnings	Oct 28 BMO	SMA200	27.45%	Avg Volume	1.92M	Price	92.59
IPO	Nov 04, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	40.71% 8.91%	Trades		Volume	2,402,142	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-08-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-06-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$89
Aug-01-25	Initiated	Barclays	Overweight	$90
Jun-16-25	Upgrade	Stifel	Hold → Buy	$107
Mar-18-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-18-25	Downgrade	Guggenheim	Buy → Neutral
Dec-17-24	Initiated	UBS	Neutral	$77
Oct-29-24	Upgrade	BofA Securities	Neutral → Buy	$68 → $90
Oct-01-24	Initiated	Wolfe Research	Outperform	$84
Sep-18-24	Downgrade	Truist	Buy → Hold	$83 → $74
Jul-02-24	Downgrade	BMO Capital Markets	Market Perform → Underperform	$52 → $48
May-23-24	Initiated	Deutsche Bank	Hold	$55
Apr-23-24	Initiated	Cantor Fitzgerald	Neutral
Feb-23-24	Initiated	Jefferies	Buy	$81
Feb-14-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Dec-13-23	Upgrade	Leerink Partners	Market Perform → Outperform	$78
Dec-04-23	Upgrade	Guggenheim	Neutral → Buy	$86
Nov-21-23	Downgrade	Goldman	Buy → Neutral	$98 → $65
Jul-25-23	Initiated	Citigroup	Buy	$82
May-04-23	Downgrade	BofA Securities	Buy → Neutral	$84

Show Previous Ratings

Oct-30-25 03:04PM	Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
09:36AM	Analyst Report: Incyte Corporation (Morningstar Research)
08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Oct-29-25 01:31AM	INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus (StockStory)
Oct-28-25 02:42PM	1 Growth Stock Under $100 to Buy Before It Soars (Barchart)
12:24PM	Loading…
12:24PM	Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) (Insider Monkey)
12:11PM	Why Incyte (INCY) Stock Is Trading Lower Today (StockStory)
11:09AM	INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:49AM	Incyte Falls After Hiked 2025 Outlook Misses Wall Street's Bullish Views (Investor's Business Daily)
09:30AM	Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Incyte (INCY) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:18AM	Incyte (NASDAQ:INCY) Reports Strong Q3 (StockStory)
07:10AM	Incyte: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Oct-27-25 12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
07:30AM	Loading…
07:30AM	Incyte and Enable Injections Announce Strategic Partnership for enFuse On-Body Delivery System (Business Wire)
Oct-26-25 11:12PM	What To Expect From Incyte's (INCY) Q3 Earnings (StockStory)
Oct-25-25 07:55PM	Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis (Business Wire)
Oct-24-25 09:57AM	Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
08:50AM	How to Find Strong Medical Stocks Slated for Positive Earnings Surprises (Zacks)
06:45AM	Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial (PR Newswire)
Oct-23-25 08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-22-25 10:00AM	GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-21-25 10:00AM	Incyte (INCY) Earnings Expected to Grow: Should You Buy? (Zacks)
08:55AM	Incyte's Quarterly Earnings Preview: What You Need to Know (Barchart)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Incyte (INCY) is a Great Choice (Zacks)
09:30AM	Will Positive Regulatory Updates Further Boost INCY Stock? (Zacks)
Oct-19-25 01:30PM	Incyte Announces Phase 1 Results for its TGFR2PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
12:26PM	Loading…
12:26PM	Incyte (INCY) Stock Is Up, What You Need To Know (StockStory)
11:40AM	INCY or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Oct-12-25 06:05PM	Data from Incytes TGFR2PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 (Business Wire)
Oct-10-25 08:44AM	Abbott to Report Q3 Earnings: Medical Devices Arm in Focus (Zacks)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
11:16AM	TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus (Zacks)
09:45AM	Intel, FedEx downgraded: Wall Street's top analyst calls (The Fly)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
08:00AM	Incyte to Report Third Quarter Financial Results (Business Wire)
Oct-07-25 12:10PM	Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-02-25 01:35AM	Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism (Insider Monkey)
12:03AM	2 Reasons to Like INCY and 1 to Stay Skeptical (StockStory)
Sep-30-25 11:40AM	INCY vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Sep-29-25 03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
Sep-25-25 01:05PM	Jim Cramer Calls Incyte "Way Too Cheap" (Insider Monkey)
Sep-24-25 04:30PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:58AM	Incyte's Povorcitinib Shows Sustained Efficacy in Phase 3 HS Trial, Supports 2025/2026 Regulatory Submissions (Insider Monkey)
Sep-23-25 10:24AM	Strength Seen in Oculis Holding AG (OCS): Can Its 6.7% Jump Turn into More Strength? (Zacks)
09:53AM	Is Incyte Stock Outperforming the S&P 500? (Barchart)
Sep-22-25 07:30AM	Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer (Business Wire)
Sep-19-25 09:53AM	INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream (Zacks)
Sep-18-25 04:21PM	Incyte Announces Additional FDA Approval of Opzelura (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis (Business Wire)
Sep-17-25 02:27PM	Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT (Insider Monkey)
09:38AM	INCY Announces New Late-Stage Data on Skin Disease Drug (Zacks)
01:00AM	Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025 (Business Wire)
Sep-11-25 11:15AM	Incyte Corporation (INCY) Advances KRAS Cancer Program (Insider Monkey)
Sep-10-25 07:30AM	Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress (Business Wire)
Sep-09-25 02:22PM	Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. (Barrons.com)
Sep-05-25 11:01AM	Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally (Investor's Business Daily)
Sep-03-25 11:30AM	Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report? (Zacks)
09:15AM	Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa (Business Wire)
Sep-02-25 03:35PM	Incyte (INCY) Stock Is Up, What You Need To Know (StockStory)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-29-25 07:14AM	Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype? (MarketBeat)
Aug-28-25 11:30AM	Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue? (Zacks)
04:57AM	Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership (Insider Monkey)
Aug-27-25 04:15PM	Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-25-25 08:00AM	Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer (Business Wire)
Aug-22-25 09:39AM	AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth (Zacks)
12:33AM	2 Mooning Stocks with Exciting Potential and 1 We Ignore (StockStory)
Aug-20-25 10:18AM	INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold? (Zacks)
08:55AM	Are Wall Street Analysts Predicting Incyte Stock Will Climb or Sink? (Barchart)
Aug-19-25 08:00AM	Incyte to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-25 10:01AM	Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks (InvestorPlace)
Aug-17-25 11:33PM	Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers (StockStory)
Aug-15-25 02:50PM	Cancer Stock Soars While This China Tech Stock Heads To New Highs (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-13-25 12:15AM	INCY Q2 Deep Dive: Product Launches and Pipeline Progress Underpin Revenue Growth (StockStory) +5.20%
12:10AM	The Top 5 Analyst Questions From Incyte's Q2 Earnings Call (StockStory)
Aug-12-25 07:08PM	Analyst Report: Incyte Corporation (Morningstar Research)
09:10AM	Wells Fargo Upgrades Incyte Corporation (INCY) to Overweight From Equal Weight (Insider Monkey)
Aug-11-25 02:00AM	Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside. (Barrons.com)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-06-25 09:36AM	Snap downgraded, Leidos upgraded: Wall Street's top analyst calls (The Fly)
08:45AM	Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer (GlobeNewswire)
Aug-05-25 04:05PM	Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis (Business Wire)
Aug-04-25 04:30PM	Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America (GlobeNewswire)
Aug-01-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:34AM	Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls (The Fly)
Jul-31-25 04:30PM	Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil (GlobeNewswire)
Jul-30-25 09:40AM	Why Incyte (INCY) is a Top Value Stock for the Long-Term (Zacks)
08:50AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
03:04AM	Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:55AM	Analyst Report: Incyte Corporation (Morningstar Research)
Jul-29-25 02:40PM	Incyte (INCY) Stock Trades Up, Here Is Why (StockStory) +10.28%
11:45AM	INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales (Zacks)
09:30AM	Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:48AM	Incyte (NASDAQ:INCY) Reports Strong Q2 (StockStory)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHRISTIANA STAMOULIS	Officer	Oct 30 '25	Proposed Sale	94.00	14,986	1,408,684		Oct 30 04:31 PM
BARRY FLANNELLY	Officer	Oct 27 '25	Proposed Sale	91.73	33,452	3,068,539		Oct 27 04:21 PM
Denton Sheila A.	EVP & General Counsel	Oct 15 '25	Option Exercise	64.25	277	17,797	26,846	Oct 17 04:01 PM
Denton Sheila A.	EVP & General Counsel	Oct 15 '25	Sale	85.13	277	23,581	26,569	Oct 17 04:01 PM
BARRY FLANNELLY	Officer	Oct 16 '25	Proposed Sale	92.38	18,495	1,708,609		Oct 16 04:01 PM
SHEILA DENTON	Officer	Oct 15 '25	Proposed Sale	85.13	277	23,581		Oct 15 04:03 PM
Denton Sheila A.	EVP & General Counsel	Oct 02 '25	Option Exercise	58.06	599	34,778	33,799	Oct 06 04:02 PM
Denton Sheila A.	EVP & General Counsel	Oct 03 '25	Sale	85.54	3,501	299,476	26,569	Oct 06 04:02 PM
Denton Sheila A.	EVP & General Counsel	Oct 02 '25	Sale	87.65	599	52,502	33,200	Oct 06 04:02 PM
SHEILA DENTON	Officer	Oct 03 '25	Proposed Sale	85.54	3,501	299,464		Oct 03 04:07 PM
SHEILA DENTON	Officer	Oct 02 '25	Proposed Sale	87.65	599	52,502		Oct 02 04:01 PM
BARRY FLANNELLY	Officer	Sep 18 '25	Proposed Sale	85.26	17,447	1,487,531		Sep 18 05:10 PM
Denton Sheila A.	EVP & General Counsel	Sep 16 '25	Option Exercise	64.25	278	17,862	33,478	Sep 18 04:06 PM
Denton Sheila A.	EVP & General Counsel	Sep 16 '25	Sale	83.15	278	23,116	33,200	Sep 18 04:06 PM
SHEILA DENTON	Officer	Sep 16 '25	Proposed Sale	83.15	278	23,116		Sep 16 04:03 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Option Exercise	58.06	598	34,720	33,798	Sep 04 04:04 PM
Denton Sheila A.	EVP & General Counsel	Sep 02 '25	Sale	84.97	598	50,812	33,200	Sep 04 04:04 PM
SHEILA DENTON	Officer	Sep 02 '25	Proposed Sale	84.97	598	50,812		Sep 02 04:07 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Option Exercise	64.25	277	17,797	33,477	Aug 19 04:13 PM
Denton Sheila A.	EVP & General Counsel	Aug 15 '25	Sale	86.81	277	24,046	33,200	Aug 19 04:13 PM
SHEILA DENTON	Officer	Aug 15 '25	Proposed Sale	86.81	277	24,046		Aug 15 04:05 PM
BARRY FLANNELLY	Officer	Aug 13 '25	Proposed Sale	82.51	75,963	6,267,540		Aug 13 04:18 PM
BARRY FLANNELLY	Officer	Aug 12 '25	Proposed Sale	80.00	14,037	1,122,970		Aug 12 04:21 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Option Exercise	58.06	598	34,720	33,798	Aug 06 04:03 PM
Denton Sheila A.	EVP & General Counsel	Aug 04 '25	Sale	75.77	598	45,310	33,200	Aug 06 04:03 PM
SHEILA DENTON	Officer	Aug 04 '25	Proposed Sale	75.77	598	45,310		Aug 04 04:05 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 21 '25	Sale	67.94	3,706	251,786	102,886	Jul 23 03:56 PM
STEVEN STEIN	Officer	Jul 21 '25	Proposed Sale	67.94	3,706	251,786		Jul 21 04:01 PM
Flannelly Barry P	EVP & General Manager US	Jul 16 '25	Sale	68.36	1,340	91,602	35,149	Jul 17 04:06 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 16 '25	Sale	68.36	983	67,198	40,540	Jul 17 04:05 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Option Exercise	64.25	3,330	213,952	29,834	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 15 '25	Sale	69.86	3,330	232,634	26,504	Jul 17 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jul 16 '25	Sale	68.36	785	53,663	33,200	Jul 17 04:04 PM
VIJAY IYENGAR	Officer	Jul 16 '25	Proposed Sale	68.36	983	67,198		Jul 16 04:07 PM
BARRY FLANNELLY	Officer	Jul 16 '25	Proposed Sale	68.36	1,340	91,602		Jul 16 04:06 PM
Stein Steven H	EVP & Chief Medical Officer	Jul 14 '25	Sale	68.47	14,952	1,023,763	97,466	Jul 16 04:05 PM
SHEILA DENTON	Officer	Jul 16 '25	Proposed Sale	68.36	785	53,663		Jul 16 04:02 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 15 '25	Sale	69.86	1,177	82,225	35,929	Jul 16 04:02 PM
Flannelly Barry P	EVP & General Manager US	Jul 15 '25	Sale	69.86	1,192	83,273	37,630	Jul 16 04:02 PM
BARRY FLANNELLY	Officer	Jul 15 '25	Proposed Sale	69.86	1,192	83,273		Jul 15 04:41 PM
SHEILA DENTON	Officer	Jul 15 '25	Proposed Sale	69.86	3,330	232,634		Jul 15 04:37 PM
VIJAY IYENGAR	Officer	Jul 15 '25	Proposed Sale	69.86	1,177	82,225		Jul 15 04:20 PM
STEVEN STEIN	Officer	Jul 14 '25	Proposed Sale	68.47	14,952	1,023,714		Jul 14 04:03 PM
Flannelly Barry P	EVP & General Manager US	Jul 03 '25	Sale	68.15	10,903	743,039	39,744	Jul 07 04:46 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Option Exercise	58.06	599	34,778	27,103	Jul 07 04:44 PM
Denton Sheila A.	EVP & General Counsel	Jul 02 '25	Sale	68.61	599	41,097	26,504	Jul 07 04:44 PM
Iyengar Vijay K	EVP, GMAPPS	Jul 03 '25	Sale	68.15	8,617	587,275	37,701	Jul 07 04:43 PM
BARRY FLANNELLY	Officer	Jul 03 '25	Proposed Sale	68.15	10,903	743,048		Jul 03 03:10 PM
VIJAY IYENGAR	Officer	Jul 03 '25	Proposed Sale	68.15	8,617	587,272		Jul 03 02:46 PM
SHEILA DENTON	Officer	Jul 02 '25	Proposed Sale	68.61	599	41,097		Jul 02 04:27 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Option Exercise	58.06	1,795	104,218	28,299	Jun 05 04:04 PM
Denton Sheila A.	EVP & General Counsel	Jun 03 '25	Sale	68.00	1,795	122,060	26,504	Jun 05 04:04 PM
SHEILA DENTON	Officer	Jun 03 '25	Proposed Sale	68.00	1,795	122,060		Jun 03 04:06 PM
Tray Thomas	Principal Accounting Officer	May 30 '25	Sale	65.71	963	63,279	22,654	Jun 03 04:00 PM
Tray Thomas	Principal Accounting Officer	Jun 02 '25	Sale	64.88	651	42,237	22,003	Jun 03 04:00 PM
THOMAS R TRAY	Officer	Jun 02 '25	Proposed Sale	64.88	651	42,237		Jun 02 04:26 PM
THOMAS R TRAY	Officer	May 30 '25	Proposed Sale	65.71	963	63,279		May 30 04:03 PM
Flannelly Barry P	EVP & General Manager US	Mar 14 '25	Sale	67.69	19,807	1,340,656	33,567	Mar 18 04:01 PM
BARRY FLANNELLY	Officer	Mar 14 '25	Proposed Sale	67.69	19,807	1,340,728		Mar 14 04:11 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Option Exercise	58.06	599	34,778	26,447	Mar 06 04:56 PM
Denton Sheila A.	EVP & General Counsel	Mar 04 '25	Sale	69.99	599	41,924	25,848	Mar 06 04:56 PM
SHEILA DENTON	Officer	Mar 04 '25	Proposed Sale	69.99	599	41,924		Mar 04 05:12 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Option Exercise	58.06	9,574	555,866	39,917	Feb 28 06:34 PM
Denton Sheila A.	EVP & General Counsel	Feb 26 '25	Sale	74.07	14,069	1,042,136	25,848	Feb 28 06:34 PM
SHEILA DENTON	Officer	Feb 26 '25	Proposed Sale	74.07	14,069	1,042,138		Feb 26 04:04 PM
Stein Steven H	EVP & Chief Medical Officer	Jan 21 '25	Sale	72.69	12,352	897,867	66,967	Jan 22 04:05 PM
STEVEN STEIN	Officer	Jan 21 '25	Proposed Sale	72.69	12,352	897,906		Jan 21 04:03 PM
Tray Thomas	Principal Accounting Officer	Dec 13 '24	Sale	70.64	650	45,916	23,962	Dec 17 12:37 PM
Tray Thomas	Principal Accounting Officer	Dec 16 '24	Sale	69.31	650	45,052	23,312	Dec 17 12:37 PM
THOMAS R TRAY	Officer	Dec 16 '24	Proposed Sale	69.31	650	45,052		Dec 16 04:04 PM
Iyengar Vijay K	EVP, GMAPPS	Nov 29 '24	Sale	75.38	6,043	455,544	30,658	Dec 03 12:52 PM
VIJAY IYENGAR	Officer	Nov 29 '24	Proposed Sale	75.39	6,043	455,555		Nov 29 01:28 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Option Exercise	70.03	3,680	257,719	61,722	Nov 08 12:48 PM
Flannelly Barry P	EVP & General Manager US	Nov 06 '24	Sale	79.68	3,680	293,210	58,042	Nov 08 12:48 PM
BARRY FLANNELLY	Officer	Nov 06 '24	Proposed Sale	79.68	3,680	293,210		Nov 06 04:15 PM

Open in Screener

NOTV

Inotiv Inc

Oct 30 • 04:00PM ET

1.33

0.00 0.00 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: CRL ICON IQV MEDP CROX CERS BMRN CTLT EXEL NBIX

| Held by: VTI VXF PRFZ IWC

Index	-	P/E	-	EPS (ttm)	-2.69	Insider Own	13.79%	Shs Outstand	34.35M	Perf Week	-1.48%
Market Cap	45.69M	Forward P/E	-	EPS next Y	-1.80	Insider Trans	-0.21%	Shs Float	29.62M	Perf Month	-11.92%
Enterprise Value	487.69M	PEG	-	EPS next Q	-0.46	Inst Own	24.76%	Short Float	6.57%	Perf Quarter	-30.73%
Income	-78.96M	P/S	0.09	EPS this Y	44.15%	Inst Trans	-0.15%	Short Ratio	4.91	Perf Half Y	-32.83%
Sales	505.30M	P/B	0.32	EPS next Y	23.08%	ROA	-10.29%	Short Interest	1.95M	Perf YTD	-67.87%
Book/sh	4.19	P/C	7.36	EPS next 5Y	-	ROE	-48.46%	52W High	6.48 -79.48%	Perf Year	-26.92%
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	- -122.90%	ROIC	-13.70%	52W Low	1.15 15.65%	Perf 3Y	-93.98%
Dividend Est.	-	EV/EBITDA	29.41	Sales past 3/5Y	76.27% 62.27%	Gross Margin	12.13%	Volatility	8.36% 8.46%	Perf 5Y	-74.62%
Dividend TTM	-	EV/Sales	0.97	EPS Y/Y TTM	29.83%	Oper. Margin	-7.92%	ATR (14)	0.11	Perf 10Y	-18.90%
Dividend Ex-Date	-	Quick Ratio	0.81	Sales Y/Y TTM	0.85%	Profit Margin	-15.63%	RSI (14)	42.83	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.29	EPS Q/Q	49.01%	SMA20	-4.32%	Beta	4.20	Target Price	7.00
Payout	-	Debt/Eq	3.12	Sales Q/Q	23.54%	SMA50	-9.67%	Rel Volume	0.42	Prev Close	1.33
Employees	2075	LT Debt/Eq	3.01	Earnings	Aug 06 AMC	SMA200	-42.50%	Avg Volume	396.16K	Price	1.33
IPO	Nov 25, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.61% 2.87%	Trades		Volume	168,315	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-24	Downgrade	Jefferies	Buy → Hold	$11.50 → $3.75
Feb-09-24	Upgrade	Jefferies	Hold → Buy	$3 → $11.50
Jul-20-23	Initiated	Wells Fargo	Overweight	$9
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $8
Jan-11-23	Upgrade	Lake Street	Hold → Buy	$4 → $10
Nov-18-22	Downgrade	Lake Street	Buy → Hold	$60 → $7
Oct-04-22	Initiated	Jefferies	Buy	$27
Jan-31-22	Initiated	Lake Street	Buy	$60
Sep-20-21	Initiated	Craig Hallum	Buy	$45

Oct-24-25 10:20AM	Halper Sadeh LLC Encourages Inotiv, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-21-25 04:05PM	Inotiv, Inc. to Participate in Three Investor Conferences in November 2025 (GlobeNewswire)
Aug-20-25 07:37AM	Pharmaceutical firm Inotiv investigating ransomware attack that disrupted operations (Cybersecurity Dive)
Aug-13-25 07:00AM	Inotiv, Inc. to Participate in Three Investor Conferences in September 2025 (GlobeNewswire)
Aug-06-25 09:16PM	CORRECTING and REPLACING - Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) +5.54% -10.50%
05:50PM	Loading…
05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire)
Aug-05-25 07:15AM	Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-23-25 07:00AM	Inotiv, Inc. to Report Fiscal 2025 Third Quarter Financial Results and Host Conference Call on Wednesday, August 6, 2025 (GlobeNewswire) +7.14%
May-22-25 04:05PM	Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-08-25 03:28AM	Inotiv Inc (NOTV) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Optimizations ... (GuruFocus.com) +10.20%
12:05AM	Inotiv outlines revised RMS site optimization plan with $6.5M investment and $6M-$7M annual savings projection (Seeking Alpha)
12:03AM	Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript (Seeking Alpha)
May-07-25 06:45PM	Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.20%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire)
08:45AM	Loading…
May-06-25 08:45AM	Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates (Zacks) -13.73%
May-01-25 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-30-25 10:01AM	Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-23-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 (GlobeNewswire) +7.27% +8.47%
Feb-06-25 02:14AM	Inotiv Inc (NOTV) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth ... (GuruFocus.com) -6.22%
Feb-05-25 04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update (GlobeNewswire) -7.01%
Jan-22-25 04:05PM	Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 (GlobeNewswire)
Dec-30-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million (GlobeNewswire) -11.06%
Dec-23-24 04:05PM	Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million (GlobeNewswire) +14.97%
Dec-18-24 08:00AM	Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares (GlobeNewswire) -28.83%
Dec-17-24 04:03PM	Inotiv, Inc. Launches Proposed Public Offering of Common Shares (GlobeNewswire)
Dec-04-24 02:00AM	Inotiv Inc (NOTV) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Operational Challenges (GuruFocus.com) -6.21%
Dec-03-24 04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire) +7.44%
Dec-02-24 07:02AM	Inotiv Inc (NOTV) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +6.56%
Nov-21-24 08:30AM	Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 (GlobeNewswire) +6.23%
04:05PM	Loading…
Nov-20-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 (GlobeNewswire) +15.05%
Nov-07-24 08:00AM	Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences (GlobeNewswire) +8.23%
Oct-09-24 05:54PM	Inotiv Inc (NOTV) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... (GuruFocus.com)
Sep-16-24 08:00AM	Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity (GlobeNewswire) +18.97%
Aug-28-24 04:05PM	Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference (GlobeNewswire) +9.29%
Aug-08-24 06:15PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +5.66%
04:05PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 (GlobeNewswire)
Jul-09-24 06:50AM	3 Breakout Stocks to Buy Before They Make Headlines (InvestorPlace)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-10-24 07:30AM	Inotiv, Inc. Provides Business Updates (GlobeNewswire) +6.43%
Jun-03-24 02:49PM	Company that bred beagles for research pleads guilty to neglect, ordered to pay record $35M fine (Associated Press Finance) +16.04%
01:24PM	Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility (GlobeNewswire)
May-23-24 04:15PM	Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences (GlobeNewswire)
May-15-24 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.66%
04:05PM	Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
May-14-24 08:19AM	Why Is Inotiv (NOTV) Stock Down 35% Today? (InvestorPlace) -49.16%
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Wednesday, May 15, 2024 (GlobeNewswire)
May-10-24 05:20AM	Inotiv Delays Release of Fiscal Q2 Results (MT Newswires) -9.62%
May-09-24 06:56PM	Inotiv, Inc. Reschedules its Fiscal 2024 Second Quarter Results (GlobeNewswire) -12.42%
Apr-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 (GlobeNewswire) -7.65%
Apr-03-24 08:50AM	Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Apr-02-24 08:50AM	Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors (Zacks)
Mar-25-24 09:40AM	Is Inotiv (NOTV) a Great Value Stock Right Now? (Zacks)
Mar-18-24 08:50AM	Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going (Zacks)
Mar-12-24 04:42PM	Rocket Stocks: 3 Picks That Could Skyrocket Your Portfolio by 2025 (InvestorPlace) +9.96%
Mar-07-24 04:20PM	3 Stocks That Could Fast-Track Your Millionaire Status (InvestorPlace) +6.54%
12:00PM	Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy? (Zacks)
08:50AM	Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock (Zacks)
Mar-01-24 09:40AM	Should Value Investors Buy Inotiv (NOTV) Stock? (Zacks) +7.25%
Feb-29-24 08:50AM	Here's What Could Help Inotiv, Inc. (NOTV) Maintain Its Recent Price Strength (Zacks) +13.57%
Feb-27-24 01:34PM	3 Overlooked Stocks with Potential for 500% Growth by 2025 (InvestorPlace)
Feb-20-24 07:38AM	Millionaire-Makers: 3 Game-Changing Stocks Ready for Historic Gains (InvestorPlace) +6.52%
Feb-19-24 08:50AM	Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-14-24 09:40AM	Are Investors Undervaluing Inotiv (NOTV) Right Now? (Zacks) +10.23%
Feb-09-24 08:25AM	Inotiv, Inc. (NASDAQ:NOTV) Q1 2024 Earnings Call Transcript (Insider Monkey) +15.35%
Feb-08-24 09:55AM	Inotiv Inc (NOTV) Reports Revenue Growth and Reduced Net Loss in Q1 FY 2024 (GuruFocus.com) +16.85%
08:54AM	Q1 2024 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 06:10PM	Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update (GlobeNewswire)
Jan-29-24 04:05PM	Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024 (GlobeNewswire) -5.22%
Jan-27-24 09:00AM	Big Pharmas great lab monkey shortage: A crackdown on smuggling is causing chaos in Americas vital drug development pipeline (Fortune)
Dec-16-23 03:01PM	Insider Buying: COO John Beattie Acquires 47,966 Shares of Inotiv Inc (NOTV) (GuruFocus.com)
Dec-15-23 08:50AM	Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Dec-14-23 08:14AM	Inotiv, Inc. (NASDAQ:NOTV) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.32%
Dec-12-23 07:45AM	Q4 2023 Inotiv Inc Earnings Call (Thomson Reuters StreetEvents) -15.84%
Dec-11-23 09:54PM	NOTV Stock Earnings: Inotiv Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.36%
04:05PM	Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Dec-06-23 04:30PM	Inotiv, Inc. Announces Plan to Insource North American Transportation Operations (GlobeNewswire) +14.55%
Nov-27-23 04:05PM	Inotiv, Inc. to Report Fiscal 2023 Fourth Quarter and Full Year Results and Host Conference Call on Monday, December 11, 2023 (GlobeNewswire) -13.73% +6.12%
Nov-13-23 04:05PM	Inotiv Provides Business Updates and Upcoming Investor Conferences Update (GlobeNewswire) +16.48%
Nov-08-23 07:30AM	Inotiv Ranked Number 127 Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 (GlobeNewswire)
Nov-01-23 08:00AM	Inotiv, Inc. to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 08:00AM	Inotiv, Inc. Announces Changes to its Board Composition (GlobeNewswire) +21.95%
Aug-29-23 06:47PM	Inotiv Announces the Sale of its Israeli Businesses to Harlan Holdings Ltd. (GlobeNewswire)
Aug-24-23 04:05PM	Inotiv, Inc. to Participate in Upcoming September 2023 Investor Conferences (GlobeNewswire) -6.55%
Aug-15-23 03:31PM	Inotiv Faces SEC Probe on Imports of Monkeys From Asia (The Wall Street Journal) -6.86%
Aug-10-23 06:15PM	Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates (Zacks) -35.63%
04:08PM	Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update (GlobeNewswire)
Jul-24-23 04:35PM	Inotiv, Inc. to Report Fiscal 2023 Third Quarter Financial Results and Host Conference Call on Thursday, August 10, 2023 (GlobeNewswire) -5.76%
Jul-20-23 08:24PM	Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength? (Zacks) +34.52%
Jun-30-23 08:44AM	Are Options Traders Betting on a Big Move in Inotiv (NOTV) Stock? (Zacks)
Jun-05-23 09:55AM	Does Inotiv, Inc. (NOTV) Have the Potential to Rally 185.14% as Wall Street Analysts Expect? (Zacks)
May-30-23 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Inotiv, Inc. (NOTV) (Zacks)
May-25-23 08:33AM	Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference (GlobeNewswire)
May-19-23 08:33AM	Inotiv, Inc. to Participate in May Investor Conferences (GlobeNewswire)
May-18-23 09:55AM	Wall Street Analysts Predict a 168.98% Upside in Inotiv, Inc. (NOTV): Here's What You Should Know (Zacks)
May-13-23 08:15AM	Inotiv Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-11-23 05:55PM	Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -11.13%

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Neff R Matthew	Director	Oct 24 '25	Option Exercise	1.94	10,000	19,400	155,102	Oct 28 04:03 PM
Neff R Matthew	Director	Oct 01 '25	Sale	1.43	2,000	2,858	145,102	Oct 03 04:25 PM
Neff R Matthew	Director	Sep 02 '25	Sale	1.67	2,000	3,338	147,102	Sep 04 10:46 AM
Neff R Matthew	Director	Sep 02 '25	Proposed Sale	1.67	6,000	10,000		Sep 02 11:24 AM
Neff R Matthew	Director	Aug 01 '25	Sale	1.91	2,000	3,818	149,102	Aug 04 04:28 PM
Neff R Matthew	Director	Jul 01 '25	Sale	1.81	2,000	3,621	151,102	Jul 03 04:30 PM
Neff R Matthew	Director	Jun 02 '25	Sale	2.62	2,000	5,246	153,102	Jun 04 04:05 PM
Neff R Matthew	Director	Jun 02 '25	Proposed Sale	2.60	6,000	15,600		Jun 02 10:26 AM
Coelho Mary Theresa	Director	Apr 01 '25	Sale	2.35	5,500	12,916	74,303	Apr 02 04:32 PM
Coelho Mary Theresa	Director	Apr 01 '25	Proposed Sale	2.83	5,500	15,565		Apr 01 06:33 PM
Freeman Jeffrey Brennan	VP-Finance & Corp. Controller	Feb 18 '25	Sale	4.04	1,339	5,416	27,478	Feb 20 04:34 PM
Taylor Beth	Chief Financial Officer	Feb 18 '25	Sale	4.01	4,370	17,507	108,368	Feb 20 04:33 PM
Sagartz John E	Chief Strategy Officer	Feb 18 '25	Sale	3.94	2,113	8,316	707,816	Feb 20 04:33 PM
Leasure Robert Jr.	President and CEO	Feb 18 '25	Sale	3.82	73,617	281,136	956,592	Feb 20 04:32 PM
Leasure Robert Jr.	President and CEO	Jan 31 '25	Sale	4.15	22,700	94,298	1,030,209	Feb 04 04:15 PM
Taylor Beth	Chief Financial Officer	Jan 31 '25	Sale	4.46	2,054	9,171	112,738	Feb 04 04:14 PM
Sagartz John E	Chief Strategy Officer	Jan 31 '25	Sale	4.48	2,118	9,479	709,929	Feb 04 04:13 PM
Krupp Jeffrey Arthur	Chief Human Resources Officer	Jan 31 '25	Sale	4.48	2,036	9,123	29,029	Feb 04 04:12 PM
Krupp Jeffrey Arthur	Chief Human Resources Officer	Feb 03 '25	Sale	4.18	472	1,973	28,557	Feb 04 04:12 PM
Landman David	Director	Dec 19 '24	Buy	4.25	23,529	99,998	176,851	Dec 23 09:47 PM
Beattie John Gregory	Chief Operating Officer	Dec 10 '24	Buy	4.75	30,000	142,500	161,761	Dec 12 06:46 PM
Brown Nigel	Director	Dec 10 '24	Buy	4.26	7,500	31,950	65,537	Dec 10 04:13 PM
Harrington Michael J	Director	Dec 06 '24	Buy	3.98	10,000	39,822	37,500	Dec 10 08:34 AM
Landman David	Director	Dec 06 '24	Buy	4.14	100,000	414,000	153,322	Dec 10 08:31 AM

Open in Screener

ABSI

Absci Corp

Oct 30 • 04:00PM ET

4.09

-0.28 -6.41 %

Healthcare • Biotechnology • USA • NASD

Peers: INCY VRTX REGN BMRN SRPT EXEL NBIX IONS ALNY CRSP

| Held by: ARKG IWM VTI VXF IWO IBB SCHA VTWO IWC IWN

Index	RUT	P/E	-	EPS (ttm)	-0.95	Insider Own	12.69%	Shs Outstand	149.52M	Perf Week	-4.33%
Market Cap	611.55M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	0.83%	Shs Float	130.55M	Perf Month	30.67%
Enterprise Value	485.29M	PEG	-	EPS next Q	-0.20	Inst Own	60.00%	Short Float	23.79%	Perf Quarter	41.03%
Income	-113.30M	P/S	147.72	EPS this Y	7.45%	Inst Trans	2.60%	Short Ratio	5.80	Perf Half Y	34.98%
Sales	4.14M	P/B	3.01	EPS next Y	22.48%	ROA	-48.69%	Short Interest	31.06M	Perf YTD	56.11%
Book/sh	1.36	P/C	4.58	EPS next 5Y	6.35%	ROE	-57.39%	52W High	6.33 -35.39%	Perf Year	-4.66%
Cash/sh	0.89	P/FCF	-	EPS past 3/5Y	5.67% -29.30%	ROIC	-63.98%	52W Low	2.01 103.48%	Perf 3Y	32.36%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.76% 17.09%	Gross Margin	-205.97%	Volatility	6.20% 9.70%	Perf 5Y	-
Dividend TTM	-	EV/Sales	117.22	EPS Y/Y TTM	-1.34%	Oper. Margin	-2846.57%	ATR (14)	0.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.39	Sales Y/Y TTM	27.32%	Profit Margin	-2737.94%	RSI (14)	52.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.39	EPS Q/Q	-9.31%	SMA20	-2.98%	Beta	2.15	Target Price	8.13
Payout	-	Debt/Eq	0.04	Sales Q/Q	-53.31%	SMA50	25.21%	Rel Volume	0.50	Prev Close	4.37
Employees	157	LT Debt/Eq	0.02	Earnings	Nov 12 AMC	SMA200	28.11%	Avg Volume	5.36M	Price	4.09
IPO	Jul 22, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-15.05% -52.83%	Trades		Volume	2,677,328	Change	-6.41%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-02-25	Initiated	JP Morgan	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight	$7
Jan-22-25	Initiated	Needham	Buy	$9
Oct-02-24	Initiated	Guggenheim	Buy	$10
Jul-03-24	Initiated	Morgan Stanley	Overweight	$7
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$3
May-04-23	Initiated	H.C. Wainwright	Buy	$4
Aug-12-22	Downgrade	JP Morgan	Overweight → Underweight
Jul-18-22	Initiated	Truist	Buy	$8
Mar-02-22	Resumed	Cowen	Market Perform
Feb-01-22	Initiated	Berenberg	Buy	$28
Nov-10-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Oct-15-21	Resumed	Cowen	Market Perform
Aug-16-21	Initiated	Stifel	Hold	$28
Aug-16-21	Initiated	Credit Suisse	Outperform	$40
Aug-16-21	Initiated	Cowen	Market Perform
Aug-16-21	Initiated	BofA Securities	Neutral	$26

Show Previous Ratings

Oct-29-25 04:05PM	Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 (GlobeNewswire) -6.41%
Oct-27-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.39%
Oct-15-25 08:00AM	Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial (GlobeNewswire) +28.21%
Oct-13-25 12:12PM	2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (MarketBeat)
Sep-21-25 09:26AM	Absci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028 (Insider Monkey)
08:00AM	Loading…
Sep-11-25 08:00AM	Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD (GlobeNewswire) +15.13%
Aug-25-25 04:05PM	Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg (GlobeNewswire)
Aug-20-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 03:12AM	Absci Corp (ABSI) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges (GuruFocus.com) +5.05%
Aug-12-25 05:20PM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Aug-11-25 09:31AM	Absci Corp (ABSI) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-07-25 10:00AM	SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
02:00AM	Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target (GlobeNewswire)
Aug-06-25 10:00AM	Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
05:15PM	Loading…
Aug-05-25 05:15PM	Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates (Zacks)
Aug-04-25 05:15PM	Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:05PM	Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025 (GlobeNewswire)
Jul-25-25 09:56AM	Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains? (Zacks) -17.66%
Jul-24-25 08:45PM	Absci Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:54PM	Absci Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jul-11-25 07:15PM	Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target (Insider Monkey)
Jul-07-25 08:30AM	iRhythm Technologies Announces Board Member Retirements and New Director Appointments (GlobeNewswire) -6.86%
08:00AM	Absci Appoints Biopharma Leader Mary Szela to Board of Directors (GlobeNewswire)
May-20-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-14-25 08:32AM	Q1 2025 Absci Corp Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Absci Corp (ABSI) Q1 2025 Earnings Call Highlights: Transition to Clinical Stage and Strong ... (GuruFocus.com)
May-13-25 05:30PM	Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results (GlobeNewswire)
04:01PM	Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
09:35AM	Loading…
May-12-25 09:35AM	What To Expect From Absci Corp (ABSI) Q1 2025 Earnings (GuruFocus.com) +6.55%
Apr-14-25 04:05PM	Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025 (GlobeNewswire)
11:40AM	Absci: FDA Announcement Provides Only A Modest Tailwind (Seeking Alpha)
Apr-03-25 03:15PM	Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market (Seeking Alpha) -9.88%
Mar-31-25 07:15AM	Which Healthcare Stock Is the Best Buy Right Now? (MarketBeat) -7.04%
Mar-26-25 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.54%
Mar-21-25 10:57PM	Absci Corp (ABSI) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Mar-19-25 09:08AM	Q4 2024 Absci Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Absci Corp (ABSI) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Mar-18-25 04:05PM	Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Mar-04-25 04:05PM	Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 (GlobeNewswire)
04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Absci to Participate in the KeyBanc Capital Markets Healthcare Forum (GlobeNewswire)
Mar-01-25 05:19PM	Why Absci Corporation (ABSI) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-18-25 08:00AM	Absci to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-12-25 09:24AM	Is Absci Corp. (ABSI) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Feb-11-25 09:00AM	FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape (PR Newswire) +13.39%
Jan-24-25 11:54AM	Absci Corporation (ABSI): Pioneering AI-Driven Antibody Discovery with a Buy Rating from Needham (Insider Monkey)
Jan-22-25 01:22PM	Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside (Benzinga) +25.16%
08:00AM	Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-17-25 05:58PM	Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028 (PR Newswire) +11.03%
01:54PM	Absci Corporation (ABSI): AI in Biopharma Discovery (Insider Monkey)
Jan-11-25 07:40AM	Absci, Owkin announce partnership to bring together AI platforms (TipRanks)
Jan-10-25 05:48PM	Advanced Micro Devices (AMD) Invests in Absci for AI-Driven Drug Discovery with High-Performance Computing Solutions (Insider Monkey) -11.34%
07:30AM	Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery (GlobeNewswire)
Jan-08-25 01:14PM	AMD Shares Slide as HSBC Downgrades Stock Over Nvidia Concerns; Absci Collaboration Announced (GuruFocus.com)
09:12AM	Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery (Benzinga)
07:00AM	Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery (GlobeNewswire)
06:32AM	AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips (The Wall Street Journal)
Jan-06-25 08:00AM	Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health (GlobeNewswire)
Jan-02-25 08:00AM	Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:39PM	Why Absci Corporation (ABSI) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-13-24 08:10AM	Absci highlights progress, updates across proprietary pipeline (TipRanks)
Dec-12-24 08:00AM	Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 RandD Day (GlobeNewswire) -15.98%
08:00AM	Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day (GlobeNewswire)
Nov-21-24 08:00AM	Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-20-24 09:15AM	AI's Growing Role in Transforming Healthcare Delivers Innovations in Diagnostics, Patient Care (PR Newswire)
Nov-13-24 02:07AM	Absci Corp (ABSI) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial Challenges (GuruFocus.com) -13.74%
Nov-12-24 09:23PM	Q3 2024 Absci Corp Earnings Call (Thomson Reuters StreetEvents) -14.95%
08:50AM	Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Nov-11-24 07:15AM	Absci Corp (ABSI) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com) +5.16%
Nov-07-24 08:00AM	Absci to Host R&D Day on December 12, 2024 (GlobeNewswire)
Oct-31-24 08:00AM	Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI (GlobeNewswire) -7.25%
Oct-24-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 08:00AM	Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024 (GlobeNewswire)
Aug-31-24 02:37PM	Absci Corporation (ABSI): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-30-24 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Aug-21-24 08:00AM	Absci to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 05:30PM	Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +10.99%
04:01PM	Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Aug-12-24 08:00AM	Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI (GlobeNewswire)
Jul-31-24 04:25AM	Why Is Absci Corporation (ABSI) Among the Best Micro Cap Stocks Right Now? (Insider Monkey)
Jul-10-24 08:00AM	Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024 (GlobeNewswire)
Jul-03-24 04:00PM	Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.07%
Jun-21-24 11:08AM	Is Absci Corporation (NASDAQ:ABSCI) the Best Halal Stock According to Hedge Funds? (Insider Monkey)
Jun-12-24 08:00AM	Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit (GlobeNewswire) +9.98%
May-28-24 08:00AM	Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-20-24 09:32PM	Cathie Wood Pulls the Trigger on These 2 Strong Buy Stocks (TipRanks)
May-16-24 07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
May-15-24 03:01AM	Absci Corp (ABSI) Q1 2024 Earnings Call Transcript Highlights: Strategic Advancements and ... (GuruFocus.com)
May-14-24 11:53AM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:30AM	Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-07-24 09:13AM	Absci (ABSI) to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-16-24 08:00AM	Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024 (GlobeNewswire)
Apr-10-24 11:07AM	Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last? (Zacks) -7.67%
Mar-28-24 04:05PM	Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-23-24 05:31AM	Absci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net Loss (GuruFocus.com)
Mar-21-24 02:52PM	ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pangalos Menelas N	Director	Sep 22 '25	Buy	2.66	95,785	254,788	113,960	Sep 24 04:03 PM
Bedrick Todd	SVP, CAO	Sep 22 '25	Buy	2.70	10,000	27,000	180,428	Sep 24 04:03 PM
Busch Andreas	Chief Innovation Officer	Jul 28 '25	Buy	3.04	50,000	152,000	327,264	Jul 29 08:37 AM

Open in Screener

MXCT

MaxCyte Inc

Oct 30 • 04:00PM ET

1.51

0.00 0.00 %

Healthcare • Medical Devices • USA • NASD

Peers: NTLA CRSP EDIT SGMO BEAM CRBU CDXS ABCL ALLO

| Held by: VTI IWM VXF IWN IBB VTWO VHT IWC DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-0.42	Insider Own	7.99%	Shs Outstand	106.59M	Perf Week	-6.79%
Market Cap	160.98M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	4.21%	Shs Float	98.09M	Perf Month	-5.63%
Enterprise Value	52.93M	PEG	-	EPS next Q	-0.11	Inst Own	73.03%	Short Float	3.50%	Perf Quarter	-25.98%
Income	-44.77M	P/S	4.50	EPS this Y	-9.62%	Inst Trans	-0.62%	Short Ratio	4.11	Perf Half Y	-45.88%
Sales	35.75M	P/B	0.84	EPS next Y	6.86%	ROA	-19.00%	Short Interest	3.43M	Perf YTD	-63.70%
Book/sh	1.79	P/C	1.27	EPS next 5Y	4.34%	ROE	-21.73%	52W High	5.20 -70.96%	Perf Year	-58.17%
Cash/sh	1.19	P/FCF	-	EPS past 3/5Y	-22.97% -11.37%	ROIC	-21.53%	52W Low	1.26 19.84%	Perf 3Y	-77.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.45% 12.31%	Gross Margin	68.10%	Volatility	5.01% 6.60%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.48	EPS Y/Y TTM	-24.21%	Oper. Margin	-146.80%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.71	Sales Y/Y TTM	-21.32%	Profit Margin	-125.22%	RSI (14)	44.06	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	12.39	EPS Q/Q	-29.58%	SMA20	-7.65%	Beta	1.23	Target Price	6.68
Payout	-	Debt/Eq	0.10	Sales Q/Q	-18.43%	SMA50	-1.96%	Rel Volume	0.43	Prev Close	1.51
Employees	114	LT Debt/Eq	0.09	Earnings	Nov 05 AMC	SMA200	-39.37%	Avg Volume	835.96K	Price	1.51
IPO	Dec 05, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.99% -14.44%	Trades		Volume	357,501	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-11-25	Downgrade	BTIG Research	Buy → Neutral
Aug-07-25	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-25	Initiated	Stephens	Overweight	$6
Nov-29-23	Initiated	Craig Hallum	Buy	$7
Oct-15-21	Resumed	Cowen	Outperform
Aug-24-21	Initiated	William Blair	Outperform
Aug-24-21	Initiated	Wedbush	Outperform	$36
Aug-24-21	Initiated	Stifel	Buy	$18
Aug-24-21	Initiated	Stephens	Overweight	$19
Aug-24-21	Initiated	Cowen	Outperform
Aug-24-21	Initiated	BTIG Research	Buy	$22

Show Previous Ratings

Oct-08-25 08:05AM	MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 (GlobeNewswire) +9.68%
Oct-06-25 08:05AM	MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors (GlobeNewswire)
Sep-22-25 04:30PM	MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability (GlobeNewswire) +10.32%
Aug-11-25 07:45AM	MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio (Insider Monkey)
Aug-06-25 06:10PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -29.90%
04:05PM	Loading…
04:05PM	MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance (GlobeNewswire)
Aug-05-25 10:27AM	MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-04-25 08:05AM	MaxCyte Signs Platform License Agreement with Adicet Bio (GlobeNewswire)
Jul-31-25 08:05AM	MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline (GlobeNewswire)
Jul-09-25 08:05AM	MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-01-25 01:00AM	PHC Announces Exclusive Distribution of MaxCyte® ExPERT Platform in Japan (Business Wire)
Jun-11-25 02:00AM	MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies (GlobeNewswire)
May-13-25 10:51AM	MaxCyte, Inc. (MXCT): A Bull Case Theory (Insider Monkey)
May-08-25 03:27AM	MaxCyte Inc (MXCT) Q1 2025 Earnings Call Highlights: Strong Revenue Alignment Amidst Growth ... (GuruFocus.com) -11.31%
May-07-25 06:30PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance (GlobeNewswire)
Apr-10-25 02:00AM	MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire) -7.51%
Apr-08-25 09:35AM	Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT) (Zacks) -5.67%
Apr-07-25 09:35AM	Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround (Zacks)
Apr-04-25 12:00PM	MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know (Zacks) -5.77%
Mar-12-25 03:07AM	MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges (GuruFocus.com) -8.36%
Mar-11-25 04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance (GlobeNewswire)
Feb-12-25 02:00AM	MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs (GlobeNewswire)
Feb-07-25 02:00AM	MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-30-25 02:00AM	MaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments (GlobeNewswire)
Jan-15-25 12:00PM	All You Need to Know About MaxCyte (MXCT) Rating Upgrade to Strong Buy (Zacks)
Jan-13-25 03:05AM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) +11.59%
Dec-23-24 02:00AM	MaxCyte Announces Retirement of Board Member Art Mandell (GlobeNewswire)
Dec-09-24 02:00AM	MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance (GlobeNewswire) +15.83%
Nov-13-24 08:05AM	MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics (GlobeNewswire)
02:00PM	Loading…
Nov-07-24 02:00PM	MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ... (GuruFocus.com) -10.82%
Nov-06-24 05:55PM	MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Oct-31-24 08:05AM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-16-24 12:00PM	MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Oct-15-24 08:05AM	MaxCyte Appoints Cynthia Collins to its Board of Directors (GlobeNewswire)
Oct-11-24 08:05AM	MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 (GlobeNewswire)
Oct-10-24 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer (GlobeNewswire)
Oct-09-24 05:08PM	MaxCyte Inc (MXCT) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Core Challenges (GuruFocus.com) -5.41%
Sep-17-24 03:32AM	MaxCyte and Kamau Therapeutics sign platform license agreement (Pharmaceutical Technology)
Sep-16-24 02:00AM	MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases (GlobeNewswire)
Sep-05-24 04:05PM	MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference (GlobeNewswire)
Aug-06-24 05:50PM	MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.31%
04:05PM	MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance (GlobeNewswire)
Jul-17-24 08:50AM	MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-09-24 04:05PM	MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-13-24 09:55AM	Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect? (Zacks)
08:50AM	Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why (Zacks)
Jun-11-24 01:30AM	Insider Buying: President and CEO Maher Masoud Acquires 100,000 Shares of MaxCyte Inc (MXCT) (GuruFocus.com) -5.65%
May-29-24 08:05AM	MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference (GlobeNewswire)
May-22-24 08:05AM	MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development (GlobeNewswire)
May-12-24 08:19AM	MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 02:39PM	MaxCyte Shares Rise Sharply After Q1 Results Beat (MT Newswires) +18.07%
06:35AM	Q1 2024 MaxCyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:58AM	MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ... (GuruFocus.com)
May-07-24 08:58PM	MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance (GlobeNewswire)
Apr-10-24 08:05AM	MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-02-24 08:05AM	MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs) (GlobeNewswire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-13-24 08:17AM	11 Oversold Healthcare Stocks To Buy Right Now (Insider Monkey)
Mar-12-24 05:31PM	MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
Mar-04-24 04:05PM	MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results (GlobeNewswire) -12.21%
Feb-09-24 08:05AM	MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-30-24 08:05AM	MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers (GlobeNewswire)
Jan-23-24 08:05AM	MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs (GlobeNewswire)
Jan-08-24 04:05PM	MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +13.73%
Jan-03-24 08:05AM	MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline (GlobeNewswire) -11.60%
Jan-02-24 02:00AM	MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director (GlobeNewswire) +6.38%
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey) +9.01%
Dec-11-23 04:05PM	MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 (GlobeNewswire)
Dec-07-23 11:05AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 124,450 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Dec-02-23 09:04AM	Insider Sell Alert: President and CEO Douglas Doerfler Sells 25,550 Shares of MaxCyte Inc (MXCT) (GuruFocus.com)
Nov-16-23 08:05AM	MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member (GlobeNewswire)
Nov-09-23 12:57PM	MaxCyte, Inc. (NASDAQ:MXCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:05PM	MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance (GlobeNewswire)
Nov-06-23 04:05PM	MaxCyte to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-23 12:59PM	Why Shares of MaxCyte Are Plummeting on Thursday (Motley Fool) -20.64%
08:47AM	Why Is MaxCyte (MXCT) Stock Down 21% Today? (InvestorPlace)
Oct-04-23 04:05PM	MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance (GlobeNewswire) +9.00%
Sep-06-23 08:05AM	MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing (GlobeNewswire)
Sep-05-23 08:05AM	MaxCyte to Participate in Baird Global Healthcare Conference (GlobeNewswire)
Aug-09-23 04:05PM	MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire) -10.44%
Aug-01-23 08:05AM	MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients (GlobeNewswire)
Jul-13-23 08:05AM	MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023 (GlobeNewswire)
Jul-10-23 08:05AM	MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies (GlobeNewswire) +7.78%
Jul-08-23 04:54AM	MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company (Simply Wall St.)
Jul-06-23 08:05AM	MaxCyte Signs Strategic Platform License with Lyell Immunopharma (GlobeNewswire)
Jun-01-23 04:05PM	MaxCyte to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-30-23 08:18AM	Companies Like MaxCyte (LON:MXCT) Are In A Position To Invest In Growth (Simply Wall St.)
May-14-23 03:11AM	Earnings Working Against MaxCyte, Inc.'s (LON:MXCT) Share Price Following 28% Dive (Simply Wall St.)
May-10-23 05:25PM	MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -19.78%
04:05PM	MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance (GlobeNewswire)
May-04-23 08:05AM	MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform (GlobeNewswire)
Apr-28-23 05:03AM	MaxCyte, Inc. (LON:MXCT) insider upped their holding by 400% earlier this year (Simply Wall St.)
Apr-27-23 06:36PM	7 Small-Cap Biotech Stocks with Massive Potential (InvestorPlace)
Apr-12-23 04:05PM	MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-06-23 09:30AM	The three-year returns have been strong for MaxCyte (LON:MXCT) shareholders despite underlying losses increasing (Simply Wall St.)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hemrajani Rekha	Director	Jun 25 '25	Sale	2.09	10,684	22,378	39,893	Aug 27 05:12 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Aug 13 '25	Buy	1.29	50,000	64,500	161,811	Aug 13 07:48 PM
Masoud Maher	President and CEO	Aug 13 '25	Buy	1.37	75,000	102,915	175,000	Aug 13 07:47 PM
Erck Stanley C	Director	Aug 13 '25	Buy	1.37	100,000	137,220	398,328	Aug 13 07:47 PM
DOUGLAS RICHARD	Director	Aug 13 '25	Buy	1.39	80,000	111,040	230,577	Aug 13 07:46 PM
Brooke William W	Director	Aug 13 '25	Buy	1.29	50,000	64,500	150,879	Aug 13 07:45 PM
Hemrajani Rekha	Director	Jun 25 '25	Proposed Sale	2.09	10,684	22,378		Jun 25 04:05 PM
Soleymannezhad Ali	Chief Commercial Officer	Mar 18 '25	Sale	3.18	1,211	3,850	59,439	Mar 20 06:49 PM
Sandoval David I.	GENERAL COUNSEL	Mar 18 '25	Sale	3.18	353	1,122	64,219	Mar 20 06:47 PM
Swirsky Douglas J	CHIEF FINANCIAL OFFICER	Mar 18 '25	Sale	3.18	6,939	22,061	111,811	Mar 20 06:08 PM
Johnston John Joseph	Director	Jan 27 '25	Option Exercise	2.93	3,000	8,796	144,950	Jan 29 04:13 PM
Johnston John Joseph	Director	Jan 27 '25	Sale	4.64	3,000	13,935	141,950	Jan 29 04:13 PM
Sandoval David I.	GENERAL COUNSEL	Jan 13 '25	Sale	4.54	4,466	20,272	41,447	Jan 14 04:03 PM
Johnston John Joseph	Director	Dec 26 '24	Option Exercise	2.93	3,000	8,796	144,950	Dec 30 04:15 PM
Johnston John Joseph	Director	Dec 26 '24	Sale	4.01	3,000	12,021	141,950	Dec 30 04:15 PM
Johnston John Joseph	Affiliate	Dec 26 '24	Proposed Sale	4.11	12,000	49,320		Dec 26 04:16 PM
Johnston John Joseph	Director	Dec 09 '24	Option Exercise	2.35	2,495	5,863	144,445	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Option Exercise	2.93	505	1,478	142,455	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 09 '24	Sale	3.79	2,495	9,459	141,950	Dec 10 04:30 PM
Johnston John Joseph	Director	Dec 06 '24	Sale	3.70	505	1,869	141,950	Dec 10 04:30 PM
Erck Stanley C	Director	Nov 01 '24	Option Exercise	0.04	47,689	1,908	316,807	Nov 05 04:25 PM
Erck Stanley C	Director	Nov 01 '24	Sale	3.72	47,689	177,403	269,118	Nov 05 04:25 PM

CRL Charles River Laboratories International Inc daily Stock Chart

Peers: IQV LDOS MEDP CVS PFE ILMN BMY LH MRK

| Held by: VTI VOO RSP VB VBR IVV SPY XLV IBB IWR

Index	S&P 500	P/E	-	EPS (ttm)	-1.32	Insider Own	1.12%	Shs Outstand	49.21M	Perf Week	-6.21%
Market Cap	8.81B	Forward P/E	16.51	EPS next Y	10.85	Insider Trans	-0.36%	Shs Float	48.66M	Perf Month	5.06%
Enterprise Value	11.47B	PEG	-	EPS next Q	2.34	Inst Own	102.62%	Short Float	4.29%	Perf Quarter	7.31%
Income	-69.22M	P/S	2.19	EPS this Y	-1.17%	Inst Trans	-6.60%	Short Ratio	2.17	Perf Half Y	53.23%
Sales	4.03B	P/B	2.63	EPS next Y	6.39%	ROA	-0.89%	Short Interest	2.09M	Perf YTD	-2.97%
Book/sh	68.14	P/C	48.11	EPS next 5Y	4.42%	ROE	-1.96%	52W High	230.02 -22.13%	Perf Year	-3.97%
Cash/sh	3.72	P/FCF	15.24	EPS past 3/5Y	-70.29% -47.65%	ROIC	-1.13%	52W Low	91.86 94.98%	Perf 3Y	-18.26%
Dividend Est.	-	EV/EBITDA	12.63	Sales past 3/5Y	4.59% 9.09%	Gross Margin	29.96%	Volatility	4.38% 3.48%	Perf 5Y	-23.07%
Dividend TTM	-	EV/Sales	2.85	EPS Y/Y TTM	-115.44%	Oper. Margin	11.86%	ATR (14)	6.86	Perf 10Y	177.60%
Dividend Ex-Date	-	Quick Ratio	1.10	Sales Y/Y TTM	-1.21%	Profit Margin	-1.72%	RSI (14)	52.78	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	1.36	EPS Q/Q	-38.87%	SMA20	-0.21%	Beta	1.54	Target Price	189.14
Payout	0.00%	Debt/Eq	0.83	Sales Q/Q	0.59%	SMA50	7.58%	Rel Volume	0.81	Prev Close	180.15
Employees	20100	LT Debt/Eq	0.83	Earnings	Nov 05 BMO	SMA200	15.79%	Avg Volume	960.18K	Price	179.11
IPO	Jun 23, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	24.69% 4.76%	Trades		Volume	778,641	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-02-25	Upgrade	Barclays	Equal Weight → Overweight	$195
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$195
Jul-09-25	Upgrade	Citigroup	Neutral → Buy	$200
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy	$182
May-14-25	Upgrade	TD Cowen	Hold → Buy	$179
May-08-25	Upgrade	Evercore ISI	In-line → Outperform	$170
Mar-21-25	Downgrade	Goldman	Buy → Neutral	$190 → $170
Mar-04-25	Upgrade	Citigroup	Sell → Neutral	$155 → $175
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral	$188
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral	$250 → $185
Nov-18-24	Downgrade	CLSA	Hold → Underperform	$164
Nov-07-24	Upgrade	CLSA	Underperform → Hold	$205
Oct-23-24	Initiated	CLSA	Underperform	$167
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line	$225 → $190
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$250 → $215
Oct-01-24	Downgrade	Citigroup	Neutral → Sell	$215 → $175
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral	$239 → $191

Show Previous Ratings

Oct-30-25 10:00AM	Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-27-25 07:17PM	HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Oct-24-25 10:22AM	Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
08:53AM	Here's How Charles River Stock Is Placed Ahead of Q3 Earnings (Zacks)
07:15AM	Loading…
Oct-23-25 07:15AM	What to Expect From Charles River Laboratories' Q3 2025 Earnings Report (Barchart)
Oct-22-25 08:00AM	Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development (Business Wire)
Oct-20-25 07:22PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
12:10PM	Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:00AM	Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities (Business Wire)
Oct-15-25 08:00AM	Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption (Business Wire)
Oct-14-25 08:00AM	Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call (Business Wire)
12:02AM	3 Reasons to Avoid CRL and 1 Stock to Buy Instead (StockStory)
Oct-10-25 11:50AM	3 Medical Service Industry Stocks Poised to Counter Workforce Issues (Zacks)
Oct-08-25 11:34PM	Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
08:00AM	Loading…
08:00AM	Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing (Business Wire)
Oct-06-25 09:15AM	Pediatrix Medical Group, Inc. (MD) Soars to 52-Week High, Time to Cash Out? (Zacks)
Oct-04-25 08:31AM	Charles River price target raised to $200 from $190 at Evercore ISI (TipRanks)
Oct-03-25 04:16PM	S&P 500 Stocks: These 5 Lead As Index Hits Record High (Investor's Business Daily)
01:05PM	Charles River Laboratories (CRL) Stock Is Up, What You Need To Know (StockStory)
Oct-02-25 11:36AM	Why Charles River Laboratories (CRL) Stock Is Up Today (StockStory)
09:40AM	Nike upgraded, RH downgraded: Wall Street's top analyst calls (The Fly)
09:34AM	Life science tools Q3 preview: Barclays ups Charles River, downgrades Medpace (Investing.com)
Sep-24-25 01:59AM	Is Charles River Laboratories Stock Underperforming the Nasdaq? (Barchart)
Sep-18-25 07:31PM	Mr Wonderful Kevin O'Leary Says Bitcoin, Ethereum Enough To 'Capture The Promise' Of Crypto, Advises Against 'Irrelevant' Tokens (Benzinga)
Sep-17-25 08:27AM	Here's Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL) (Insider Monkey)
Sep-16-25 07:36AM	Insulet names new CFO; Dexcom CEO on leave (MedTech Dive)
07:05AM	Charles River Laboratories Announces Chief Financial Officer Transition (Business Wire)
Sep-12-25 08:44AM	CRL Stock Rises Following New Strategic Oncology Collaborations (Zacks)
Sep-11-25 08:00AM	Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer (Business Wire)
12:35AM	Loading…
12:35AM	3 Unpopular Stocks That Concern Us (StockStory)
Sep-09-25 12:11PM	Jefferies backs IQVIA and Charles River, cuts ICON on customer losses (Investing.com)
09:35AM	Lululemon downgraded, Dick's Sporting upgraded: Wall Street's top analyst calls (The Fly)
Sep-08-25 08:00AM	Charles River Laboratories to Present at Baird and Morgan Stanley Conferences (Business Wire)
Sep-04-25 08:50AM	Is it the Right Time to Add CRL Stock to Your Portfolio Now? (Zacks)
Sep-03-25 08:00AM	Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences (Business Wire)
Sep-02-25 11:24AM	Danaher Gains From Business Strength Amid Persisting Headwinds (Zacks)
Sep-01-25 02:18PM	Podcast: Alternative testing models to shape toxicology with time (Clinical Trials Arena)
10:21AM	Charles River Stock May Benefit From Joining EASYGEN Consortium (Zacks)
Aug-27-25 10:23AM	Charles River Laboratories Stock: Analyst Estimates & Ratings (Barchart)
Aug-26-25 08:00AM	Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing (Business Wire)
Aug-20-25 07:45AM	Factbox-Healthcare firms see growing activist investor involvement in the past year (Reuters)
Aug-18-25 07:32PM	Biotechnology company shrinks Memphis expansion plans by 500+ jobs: Here's what we know (The Commercial Appeal)
Aug-13-25 01:36AM	5 Revealing Analyst Questions From Charles River Laboratories's Q2 Earnings Call (StockStory)
Aug-12-25 03:36PM	Cambodian Monkey, Destined for Research, Dies During Transport to Canada (GlobeNewswire)
03:13AM	CRL Q2 Deep Dive: Flat Sales and Margin Pressures Offset by Demand Stabilization and Raised Outlook (StockStory)
Aug-11-25 09:15AM	Interpreting Charles River (CRL) International Revenue Trends (Zacks)
Aug-06-25 10:18PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) -10.25%
09:30AM	Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:24AM	CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View (Zacks)
08:56AM	Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2 (StockStory)
08:15AM	Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:27AM	Charles River: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Second-Quarter 2025 Results (Business Wire)
Aug-05-25 08:45AM	Organon (OGN) Beats Q2 Earnings and Revenue Estimates (Zacks)
Aug-04-25 11:26PM	Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect (StockStory)
Jul-31-25 10:00AM	Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Charles River and BioTech Social Inc. Pursue Crowdfunding Partnership (Business Wire)
Jul-30-25 10:00AM	Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:20AM	Charles River Q2 Earnings Preview: What's in Store for the Stock? (Zacks)
05:26AM	Pharma Formulation Development Outsourcing Forecast Report 2025-2033 Featuring SGS, Intertek, Recipharm, Lonza, Charles River Laboratories, Eurofins Scientific, Labcorp, Thermo Fisher Scientific (GlobeNewswire)
Jul-24-25 10:53AM	Stock Market Today: S&P 500, Nasdaq Touch Records; Rail Merger Talks; West Pharma in Focus (TheStreet) +5.45%
10:53AM	Stock Market Today: Investors Await After-Hours Results from Intel, Newmont, Deckers Brands (TheStreet)
Jul-22-25 12:10PM	Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? (Zacks) +9.06%
11:56AM	Why Are Charles River Laboratories (CRL) Shares Soaring Today (StockStory)
08:00AM	Charles River Joins Ellys Team to Drive Rare Disease Gene Therapy Development (Business Wire)
Jul-18-25 08:09AM	Here's What to Expect From Charles River Laboratories' Next Earnings Report (Barchart)
Jul-16-25 08:19AM	Is it Prudent to Retain Charles River Stock in Your Portfolio Now? (Zacks)
Jul-15-25 01:56PM	Simulations Plus Sees Weaker Demand Persist, Outlook Softens (Benzinga)
09:51AM	Charles River Laboratories International (CRL) is Expected to Gain as Industry Growth Resumes (Insider Monkey)
08:00AM	Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call (Business Wire)
Jul-08-25 08:11AM	Myrtelle Launches Manufacturing of First-in-Class Gene Therapy for Canavan Disease in Strategic Alliance with Charles River and Viralgen (PR Newswire)
Jul-04-25 01:31AM	5 Revealing Analyst Questions From Charles River Laboratories's Q1 Earnings Call (StockStory)
Jun-25-25 11:34AM	Is Charles River Laboratories Stock Underperforming the S&P 500? (Barchart)
Jun-18-25 12:02AM	3 Reasons to Sell CRL and 1 Stock to Buy Instead (StockStory)
Jun-16-25 08:00AM	Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment (Business Wire)
Jun-11-25 05:28AM	CRL Q1 Earnings Call: Regulatory Changes and Market Stabilization Shape Outlook (StockStory)
Jun-10-25 03:48PM	Megacap stocks aren't all up in 2025. But this chart shows they've trounced the S&P 500's smallest equities. (MarketWatch)
Jun-06-25 11:31AM	Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report? (Zacks)
Jun-02-25 08:12AM	Charles River Stock May Gain From Extended CHDI Research Deal on HD (Zacks)
08:00AM	Charles River Laboratories to Present at William Blair and Jefferies Conferences (Business Wire)
May-30-25 12:46AM	Charles River Laboratories International, Inc. (CRL): A Bull Case Theory (Insider Monkey)
May-28-25 08:00AM	Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntingtons Disease Research (Business Wire)
May-24-25 03:55AM	Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT (Insider Monkey)
May-20-25 08:53AM	Should You Continue to Hold Charles River Stock in Your Portfolio? (Zacks)
May-19-25 11:34PM	Drug Development Inputs & Services Stocks Q1 Results: Benchmarking Charles River Laboratories (NYSE:CRL) (StockStory)
May-13-25 09:16AM	Understanding Charles River (CRL) Reliance on International Revenue (Zacks)
08:00AM	Charles River Laboratories to Present at Bank of America Health Care Conference (Business Wire)
May-09-25 07:00AM	Eli Lilly extends Purdue alliance; EMA investigates Valneva shot (BioPharma Dive)
May-08-25 03:18AM	Charles River Laboratories International Inc (CRL) Q1 2025 Earnings Call Highlights: Navigating ... (GuruFocus.com)
May-07-25 09:34PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) +18.68%
05:19PM	S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments (Investopedia)
04:22PM	Charles River to initiate a review amid Elliott stake - Is a sale next? (Investing.com)
02:47PM	Charles river raises 2025 guidance with focus on NAMs and cost optimization (Seeking Alpha)
02:46PM	Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript (Seeking Alpha)
12:17PM	Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help. (Barrons.com)
11:51AM	Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More (Investopedia)
10:23AM	Charles River Labs Stock Soars as Firm Shakes Up Board, Launches Review (Investopedia)
09:51AM	Charles River announces strategic review including 'examination of various alternatives' (Seeking Alpha)
09:35AM	CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up (Zacks)

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The Research Models and Services segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The Discovery and Safety Assessment segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Joseph LaPlume	Officer	Aug 22 '25	Proposed Sale	152.50	400	61,000		Aug 22 01:37 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 18 '25	Sale	157.60	800	126,080	24,116	Aug 20 04:45 PM
WALLMAN RICHARD F	Former Director	Aug 18 '25	Proposed Sale	152.00	22,500	3,420,000		Aug 18 05:16 PM
Joseph LaPlume	Officer	Aug 18 '25	Proposed Sale	157.00	800	125,600		Aug 18 01:27 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 07 '25	Sale	150.04	400	60,016	24,916	Aug 08 04:18 PM
Joseph LaPlume	Officer	Aug 07 '25	Proposed Sale	150.00	400	60,000		Aug 07 02:57 PM
WALLMAN RICHARD F	Former Director	Jul 21 '25	Proposed Sale	150.00	8,500	1,275,000		Jul 21 04:21 PM
WALLMAN RICHARD F	Former Director	Jun 23 '25	Proposed Sale	137.50	4,000	550,000		Jun 25 04:34 PM
MASSARO GEORGE	Director	May 15 '25	Sale	137.57	140	19,260	5,575	May 16 04:29 PM
MASSARO GEORGE	Director	May 14 '25	Sale	140.73	140	19,703	5,715	May 15 04:41 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	May 13 '25	Sale	145.41	500	72,705	19,513	May 15 04:38 PM
MASSARO GEORGE	Director	May 14 '25	Proposed Sale	140.73	280	39,405		May 14 04:05 PM
Joseph LaPlume	Officer	May 13 '25	Proposed Sale	144.32	500	72,160		May 13 03:33 PM
FOSTER JAMES C	Chairman, President and CEO	Feb 20 '25	Buy	165.01	6,075	1,002,436	183,639	Feb 21 04:41 PM
Girshick Birgit	Corporate Executive VP & COO	Feb 20 '25	Buy	164.63	1,514	249,250	55,058	Feb 21 04:38 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Feb 20 '25	Sale	162.50	4,400	715,000	20,013	Feb 21 04:36 PM
Joseph LaPlume	Officer	Feb 20 '25	Proposed Sale	165.00	4,400	726,000		Feb 20 12:36 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.12	6,621	1,430,918	12,386	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Sale	216.50	1,000	216,500	0	Nov 12 04:38 PM
WALLMAN RICHARD F	Director	Nov 07 '24	Proposed Sale	216.01	12,161	2,626,923		Nov 07 04:23 PM

Open in Screener

NRC

National Research Corp

Oct 30 • 04:00PM ET

13.10

-0.35 -2.60 %

Healthcare • Health Information Services • USA • NASD

NRC National Research Corp daily Stock Chart

Peers: STAA EHC ACHC SMLR MD SGRY HCSG HQY ENSV SGRP

| Held by: VTI IWM VXF IWO DES SCHA DFAS VTWO SMLF RFDA

Index	RUT	P/E	18.60	EPS (ttm)	0.70	Insider Own	46.75%	Shs Outstand	22.66M	Perf Week	12.35%
Market Cap	302.13M	Forward P/E	-	EPS next Y	-	Insider Trans	0.03%	Shs Float	12.28M	Perf Month	4.80%
Enterprise Value	379.95M	PEG	-	EPS next Q	-	Inst Own	50.61%	Short Float	3.65%	Perf Quarter	4.13%
Income	16.28M	P/S	2.17	EPS this Y	-	Inst Trans	1.71%	Short Ratio	4.29	Perf Half Y	8.13%
Sales	139.10M	P/B	20.74	EPS next Y	-	ROA	12.17%	Short Interest	0.45M	Perf YTD	-25.74%
Book/sh	0.63	P/C	136.09	EPS next 5Y	-	ROE	66.53%	52W High	21.64 -39.46%	Perf Year	-30.21%
Cash/sh	0.10	P/FCF	26.00	EPS past 3/5Y	-10.60% -3.68%	ROIC	18.02%	52W Low	9.76 34.29%	Perf 3Y	-66.77%
Dividend Est.	-	EV/EBITDA	10.98	Sales past 3/5Y	-1.11% 2.25%	Gross Margin	57.02%	Volatility	8.04% 4.84%	Perf 5Y	-75.04%
Dividend TTM	0.48 (3.66%)	EV/Sales	2.73	EPS Y/Y TTM	-36.95%	Oper. Margin	19.84%	ATR (14)	0.65	Perf 10Y	-4.63%
Dividend Ex-Date	Dec 26, 2025	Quick Ratio	0.70	Sales Y/Y TTM	-3.50%	Profit Margin	11.70%	RSI (14)	55.49	Recom	3.00
Dividend Gr. 3/5Y	0.00% -9.25%	Current Ratio	0.53	EPS Q/Q	-24.87%	SMA20	9.34%	Beta	0.46	Target Price	44.00
Payout	45.99%	Debt/Eq	5.59	Sales Q/Q	-3.38%	SMA50	-4.53%	Rel Volume	1.10	Prev Close	13.45
Employees	368	LT Debt/Eq	5.31	Earnings	-	SMA200	-9.24%	Avg Volume	104.55K	Price	13.10
IPO	May 23, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	114,623	Change	-2.60%

Oct-30-25 03:21PM	National Research Corp (NRC) Q3 2025 Earnings Call Highlights: Strong TRCV Growth and Strategic ... (GuruFocus.com)
Oct-27-25 05:00PM	NRC Health Announces Third Quarter 2025 Results (Business Wire) +16.02%
Oct-15-25 09:40AM	Mercy Earns National Honor for Excellence in Patient Experience (PR Newswire)
06:45AM	NRC Health Honors 2025 Leaders in Patient Experience and Loyalty (Business Wire)
Sep-11-25 08:34AM	NRC Health Welcomes South Shore Health to Advance Patient and Employee Experience (Business Wire)
08:00AM	Loading…
Aug-28-25 08:00AM	NRC Health Announces Shane Harrison as Chief Financial Officer (Business Wire) -5.36%
Aug-01-25 01:53PM	NRC's Q2 Earnings Rise Y/Y on Cost Control and TRCV Growth (Zacks)
Jul-30-25 03:12AM	National Research Corp (NRC) Q2 2025 Earnings Call Highlights: Strong Growth Amid Leadership ... (GuruFocus.com)
Jul-28-25 05:07PM	National Research: Q2 Earnings Snapshot (Associated Press Finance)
05:00PM	NRC Health Announces Second Quarter 2025 Results (Business Wire)
Jun-26-25 02:16AM	National Research Solidifies Dividend Amid Insider Buying and Contract Growth (Insider Monkey)
May-02-25 01:13PM	NRC Q1 Earnings Dip Y/Y Amid Rising Interest Costs, Shares Up 13% (Zacks) +5.41%
Apr-28-25 05:00PM	NRC Health Announces First Quarter Results (Business Wire) +9.50%
Apr-10-25 02:01PM	A New Era of Trust: NRC Healths 2025 Experience Perspective Report Reveals Insights to Elevate the Healthcare Experience (Business Wire) -10.78%
Mar-24-25 05:00PM	National Research Corporation Declares Quarterly Dividend (Business Wire) -6.57%
07:23AM	Loading…
07:23AM	The Zacks Analyst Blog Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research (Zacks)
Mar-21-25 06:18PM	Top Stock Reports for Philip Morris, Booking Holdings & Anheuser-Busch (Zacks)
Mar-04-25 04:01PM	National Research Corporation Appoints Trent Green as Chief Executive Officer (Business Wire)
Feb-25-25 08:03AM	UofL Health Chooses NRC Health to Elevate Patient and Employee Experience Initiatives (Business Wire)
Feb-11-25 09:01AM	NRC Health Partners with UC Health to Enhance Healthcare Consumer Experience (Business Wire)
Feb-05-25 08:01AM	NRC Health ranked #1 Best in KLAS for Healthcare Experience Management (Business Wire)
Jan-27-25 05:00PM	National Research Corporation Announces Fourth Quarter Results (Business Wire) -11.85%
Jan-07-25 12:00PM	Renown Health selects NRC Health as partner to enhance patient experience and operational efficiency (Business Wire)
Nov-20-24 09:02AM	Signature Healthcare Elevates Patient Experience and Workforce Engagement Through Strategic Partnership With NRC Health (Business Wire)
Nov-12-24 09:02AM	Cooper University Health Care Selects NRC Health as New Patient Experience Partner (Business Wire)
Oct-25-24 05:00PM	National Research Corporation Announces Third Quarter Results (Business Wire)
Aug-22-24 01:00PM	AI meets empathy: NRC Health launches first AI-enabled solutions to elevate healthcare experience (Business Wire)
Aug-06-24 05:00PM	National Research Corporation Announces Second Quarter Results (Business Wire) -9.54%
May-07-24 05:00PM	National Research Corporation Announces First Quarter Results (Business Wire) -16.47%
Apr-18-24 04:23PM	National Research Corporation to Broadcast Its First Quarter 2024 Conference Call Live on the Internet (Business Wire)
11:55AM	Loading…
Apr-02-24 11:55AM	Veteran Patient Experience Executive Jennifer Baron Joins NRC Health as Its First Chief Experience Officer (Business Wire) -7.02%
Feb-13-24 05:33PM	National Research Corp (NRC) Reports Q4 and Full-Year 2023 Financial Results (GuruFocus.com) +6.13%
05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2023 Results (Business Wire)
Feb-01-24 03:00PM	National Research Corporation to Broadcast Its Fourth Quarter and Year-end 2023 Conference Call Live on the Internet (Business Wire)
10:00AM	NRC Health Expands Leadership Team to Accelerate Innovation, Meet Growing Demand for Insights and Solutions (Business Wire)
Jan-31-24 10:00AM	Yuma Regional Medical Center Selects NRC Health as New Patient Experience Partner (Business Wire)
Jan-17-24 03:00PM	National Research Corporation Elevates Leadership Team to Seize Growth Opportunity (Business Wire)
Nov-17-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Nov-09-23 02:08PM	National Research Corporation (NASDAQ:NRC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:00PM	National Research Corporation Announces Third Quarter 2023 Results (GlobeNewswire)
Oct-24-23 04:00PM	National Research Corporation to Broadcast its 2023 Third Quarter Conference Call Live on the Internet (GlobeNewswire)
Sep-26-23 08:55AM	Lurie Childrens expands partnership with NRC Health to gain valuable consumer insights (GlobeNewswire)
Sep-06-23 05:00PM	National Research Corporation Declares Special Dividend (GlobeNewswire)
Aug-31-23 06:55AM	NRC Health emphasizes its commitment to ICDs annual Patient Experience Symposium (GlobeNewswire)
Aug-29-23 08:55AM	LifeBridge Health selects NRC Health as its new patient experience partner (GlobeNewswire)
Aug-21-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-08-23 12:33PM	NRC Health unveils winners of 2023 patient experience and loyalty awards (GlobeNewswire)
Aug-01-23 05:00PM	National Research Corporation Announces Second Quarter 2023 Results (GlobeNewswire)
Jul-26-23 09:28AM	National Research (NASDAQ:NRC) Is Achieving High Returns On Its Capital (Simply Wall St.)
Jul-18-23 04:00PM	National Research Corporation to Broadcast its 2023 Second Quarter Conference Call Live on the Internet (GlobeNewswire)
Jul-12-23 11:51AM	Bryan Health Chooses NRC Health as Patient Experience Partner (GlobeNewswire)
May-31-23 12:50PM	NRC Health partners with ICD as lead sponsor of 7th Annual Patient Experience Symposium (GlobeNewswire)
May-25-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
May-12-23 02:16PM	UCHealth Partners with NRC Health to Improve Healthcare Experiences (GlobeNewswire)
May-02-23 05:00PM	National Research Corporation Announces First Quarter 2023 Results (GlobeNewswire) -7.63%
Apr-18-23 05:18PM	National Research Corporation to Broadcast its 2023 First Quarter Conference Call Live on the Internet (GlobeNewswire)
Apr-06-23 10:00AM	NRC Health reveals 2023 Pediatric Experience Perspective (GlobeNewswire)
Mar-30-23 10:00AM	NRC Health energizes healthcare organizations with digital solution to ease burnout for care teams (GlobeNewswire)
Mar-02-23 01:21PM	NRC Health offers first-of-its-kind patient experience EHR integration (GlobeNewswire)
Feb-15-23 01:00PM	Keys to delivering humanized care revealed in NRC Healths 2023 Experience Perspective (GlobeNewswire) +5.42%
Feb-14-23 05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2022 Results (GlobeNewswire)
Feb-08-23 08:01AM	NRC Health recognized as Best in KLAS for Patient Experience Improvement (GlobeNewswire)
Feb-03-23 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Jan-30-23 03:34PM	National Research Corporation to Broadcast its 2022 Fourth Quarter Conference Call Live on the Internet (GlobeNewswire)
Nov-11-22 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire) -6.56%
Nov-09-22 05:12AM	National Research Third Quarter 2022 Earnings: EPS: US$0.34 (vs US$0.38 in 3Q 2021) (Simply Wall St.)
Nov-01-22 05:00PM	National Research Corporation Announces Third Quarter 2022 Results (GlobeNewswire) -13.16%
09:00AM	NRC Health Study Finds Trust in Local Hospitals and Health Systems Increased During the Pandemic (GlobeNewswire)
Oct-19-22 02:49PM	National Research Corporation to Broadcast its 2022 Third Quarter Conference Call Live on the Internet (GlobeNewswire)
Sep-29-22 09:00AM	NRC Health Announces Sponsorship of Creative Learning Event Series Hosted by the Society for Participatory Medicine (GlobeNewswire)
Aug-23-22 05:00PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Aug-16-22 02:38PM	NRC Health Unveils Winners of 2022 Annual Awards Programs (GlobeNewswire)
Aug-12-22 11:16AM	NRC Health Announces Partnership with The Beryl Institute (GlobeNewswire)
Aug-02-22 05:00PM	National Research Corporation Announces Second Quarter 2022 Results (GlobeNewswire)
Jul-19-22 04:12PM	National Research Corporation to Broadcast its 2022 Second Quarter Conference Call Live on the Internet (GlobeNewswire)
Jul-11-22 08:03AM	National Research Corporation (NASDAQ:NRC) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.)
Jun-30-22 09:00AM	CISOs Connect Names NRC Health Chief Security and Privacy Officer Among 2022 Top 100 CISOs in the Country (GlobeNewswire)
Jun-10-22 10:12AM	We Like National Research's (NASDAQ:NRC) Returns And Here's How They're Trending (Simply Wall St.)
May-23-22 10:07AM	We Think National Research (NASDAQ:NRC) Can Manage Its Debt With Ease (Simply Wall St.)
May-20-22 05:00PM	National Research Corporation Announces Quarterly Dividend and Stock Repurchase Authorization (GlobeNewswire)
May-19-22 09:00AM	National Research Corporation Announces Appointment to Board of Directors (GlobeNewswire)
May-04-22 08:42AM	National Research's (NASDAQ:NRC) five-year total shareholder returns outpace the underlying earnings growth (Simply Wall St.)
May-03-22 05:00PM	National Research Corporation Announces First Quarter 2022 Results (GlobeNewswire)
Apr-19-22 04:35PM	National Research Corporation to Broadcast its 2022 First Quarter Conference Call Live on the Internet (GlobeNewswire)
Mar-26-22 02:24PM	Is It Smart To Buy National Research Corporation (NASDAQ:NRC) Before It Goes Ex-Dividend? (Simply Wall St.)
Mar-16-22 10:21AM	Second Annual Report from NRC Health Highlights Major Trends in Pediatric Care (GlobeNewswire)
Mar-03-22 10:21AM	What Is The Ownership Structure Like For National Research Corporation (NASDAQ:NRC)? (Simply Wall St.)
Feb-14-22 05:00PM	NRC Health Declares Quarterly Dividend (GlobeNewswire) +5.30%
Feb-08-22 05:00PM	National Research Corporation Announces Fourth Quarter and Calendar Year 2021 Results (GlobeNewswire)
Feb-01-22 11:13AM	National Research Corporation (NASDAQ:NRC) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? (Simply Wall St.) -5.87%
Jan-27-22 12:44PM	National Research Corporation to Broadcast its 2021 Fourth Quarter Conference Call Live on the Internet (GlobeNewswire)
Jan-26-22 09:38AM	Touchstone Capital, Inc. Buys Coinbase Global Inc, National Research Corp, Pfizer Inc, Sells T. ... (GuruFocus.com)
Jan-19-22 10:00AM	NRC Health Annual Consumer Trends Report Shows Declining Care Deferment, Rising Mental Health Challenges and Gaps in Telehealth (GlobeNewswire)
Dec-10-21 04:37PM	The Governance Institute Releases 2021 National Survey of Healthcare Governance (GlobeNewswire)
07:47AM	National Research (NASDAQ:NRC) Is Achieving High Returns On Its Capital (Simply Wall St.)
Nov-19-21 05:11PM	National Research Corporation Declares Quarterly Dividend (GlobeNewswire)
Nov-17-21 09:35AM	NRC Health Awards Annual Scholarship to UNL Students (GlobeNewswire)
Nov-04-21 01:35PM	We Think National Research (NASDAQ:NRC) Can Manage Its Debt With Ease (Simply Wall St.)
Nov-02-21 05:00PM	National Research Corporation Announces Third Quarter 2021 Results (GlobeNewswire)
09:00AM	NRC Health Wins Five 2021 MarCom Awards (GlobeNewswire)

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Freeman Jordan Nicole	Chief Accounting Officer	Jul 31 '25	Buy	12.97	771	10,000	771	Aug 04 04:40 PM
BEANS PATRICK E	10% Owner	May 12 '25	Buy	13.59	2,500	33,974	35,003	May 13 11:30 AM
Hays Michael D.	CEO & President	Jan 02 '25	Option Exercise	13.17	10,014	131,884	11,009	Jan 06 04:18 PM

Open in Screener

IQV

IQVIA Holdings Inc

Oct 30 • 04:00PM ET

216.47

-1.36 -0.62 %

Healthcare • Diagnostics & Research • USA • NYSE

IQV IQVIA Holdings Inc daily Stock Chart

Peers: CROX MEDP LH ICON CTLT CRL INCY

| Held by: VTI VOO VO IVV SPY VTV XLV IBB VOE RSP

Index	S&P 500	P/E	29.72	EPS (ttm)	7.28	Insider Own	0.89%	Shs Outstand	170.30M	Perf Week	-1.56%
Market Cap	36.86B	Forward P/E	16.84	EPS next Y	12.86	Insider Trans	-0.42%	Shs Float	168.79M	Perf Month	6.22%
Enterprise Value	50.21B	PEG	3.50	EPS next Q	3.40	Inst Own	101.55%	Short Float	2.81%	Perf Quarter	18.65%
Income	1.28B	P/S	2.32	EPS this Y	6.89%	Inst Trans	4.82%	Short Ratio	3.32	Perf Half Y	43.26%
Sales	15.90B	P/B	5.98	EPS next Y	8.06%	ROA	4.59%	Short Interest	4.74M	Perf YTD	10.16%
Book/sh	36.17	P/C	18.69	EPS next 5Y	8.50%	ROE	19.55%	52W High	225.91 -4.18%	Perf Year	-0.49%
Cash/sh	11.58	P/FCF	16.67	EPS past 3/5Y	14.76% 50.90%	ROIC	6.69%	52W Low	134.65 60.77%	Perf 3Y	9.52%
Dividend Est.	-	EV/EBITDA	14.82	Sales past 3/5Y	3.54% 6.79%	Gross Margin	26.67%	Volatility	2.76% 2.92%	Perf 5Y	29.26%
Dividend TTM	-	EV/Sales	3.16	EPS Y/Y TTM	-4.74%	Oper. Margin	14.19%	ATR (14)	6.15	Perf 10Y	219.80%
Dividend Ex-Date	-	Quick Ratio	0.70	Sales Y/Y TTM	3.85%	Profit Margin	8.07%	RSI (14)	64.19	Recom	1.46
Dividend Gr. 3/5Y	- -	Current Ratio	0.70	EPS Q/Q	24.60%	SMA20	3.20%	Beta	1.35	Target Price	242.39
Payout	0.00%	Debt/Eq	2.47	Sales Q/Q	5.29%	SMA50	10.19%	Rel Volume	1.23	Prev Close	217.83
Employees	88000	LT Debt/Eq	2.11	Earnings	Oct 28 BMO	SMA200	21.58%	Avg Volume	1.43M	Price	216.47
IPO	May 09, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.59% 0.50%	Trades		Volume	1,755,832	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-25	Upgrade	Robert W. Baird	Neutral → Outperform	$258
Oct-09-25	Upgrade	HSBC Securities	Hold → Buy	$235
Sep-09-25	Upgrade	Jefferies	Hold → Buy	$225
Apr-25-25	Downgrade	HSBC Securities	Buy → Hold	$160
Apr-10-25	Downgrade	Barclays	Overweight → Equal Weight	$170
Feb-03-25	Downgrade	BTIG Research	Buy → Neutral
Dec-20-24	Initiated	Stephens	Overweight	$250
Oct-14-24	Initiated	Redburn Atlantic	Buy
Sep-04-24	Initiated	RBC Capital Mkts	Outperform	$275
Jul-24-24	Downgrade	Jefferies	Buy → Hold	$266 → $242
Jun-06-24	Initiated	Goldman	Buy	$270
Feb-26-24	Initiated	Leerink Partners	Outperform	$290
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Feb-13-24	Initiated	BTIG Research	Buy	$285
Nov-02-23	Downgrade	Robert W. Baird	Outperform → Neutral	$248 → $202
Sep-06-23	Initiated	HSBC Securities	Buy	$260
Mar-17-23	Initiated	Truist	Buy	$265
Dec-06-22	Initiated	Cowen	Outperform	$251
Nov-17-22	Downgrade	Citigroup	Buy → Neutral	$275 → $245
Aug-25-22	Initiated	Credit Suisse	Outperform	$300

Show Previous Ratings

Oct-30-25 03:14PM	IQVIA Holdings Inc (IQV) Q3 2025 Earnings Call Highlights: Record Free Cash Flow and Strong ... (GuruFocus.com)
Oct-29-25 03:45PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
01:31AM	IQV Q3 Deep Dive: Clinical Research Demand and AI Initiatives Drive Steady Growth (StockStory)
Oct-28-25 08:00PM	IQVIA (IQV) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
01:09PM	IQVIA Earnings & Revenues Beat Estimates in Q3, Increase Y/Y (Zacks)
08:15AM	Loading…
08:15AM	IQVIA Holdings (IQV) Tops Q3 Earnings and Revenue Estimates (Zacks)
07:28AM	IQVIA (NYSE:IQV) Beats Q3 Sales Expectations (StockStory)
07:14AM	IQVIA: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Third-Quarter 2025 Results (Business Wire)
Oct-26-25 11:08PM	IQVIA (IQV) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-23-25 10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-22-25 10:00AM	TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-21-25 04:15PM	IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025 (Business Wire)
10:00AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-20-25 01:35PM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
04:25AM	Loading…
Oct-15-25 04:25AM	What to Expect From IQVIA Holdings Next Quarterly Earnings Report (Barchart)
Oct-10-25 12:00AM	3 Reasons to Sell IQV and 1 Stock to Buy Instead (StockStory)
Oct-09-25 09:37AM	Oracle initiated, Roblox upgraded: Wall Street's top analyst calls (The Fly)
Oct-01-25 06:48PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research) +7.29%
04:01PM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
10:10AM	Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma? (Zacks)
Sep-30-25 04:15PM	IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 (Business Wire) +5.10%
Sep-29-25 09:43AM	What Makes IQVIA (IQV) an Attractive Investment? (Insider Monkey)
Sep-19-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
08:58AM	What Makes IQVIA (IQV) a Good Investment? (Insider Monkey)
Sep-16-25 08:00AM	IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships (Business Wire)
Sep-11-25 02:16PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
06:09AM	How Is IQVIA Holdings' Stock Performance Compared to Other Health Tech Stocks? (Barchart)
Sep-10-25 08:00AM	IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management (Business Wire)
04:54AM	IQVIA Holdings Inc. (IQV) and Flagship Pioneering Partner to Accelerate Growth of Breakthrough Life Sciences Companies (Insider Monkey)
12:11PM	Loading…
Sep-09-25 12:11PM	Jefferies backs IQVIA and Charles River, cuts ICON on customer losses (Investing.com)
Sep-03-25 09:40AM	Here's Why IQVIA Holdings (IQV) is a Strong Value Stock (Zacks)
Sep-02-25 09:00AM	IQVIA Announces CFO Transition in Early 2026 (Business Wire)
Aug-29-25 11:30AM	Why Is DexCom (DXCM) Down 7% Since Last Earnings Report? (Zacks)
Aug-28-25 08:00AM	IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies (PR Newswire)
Aug-27-25 09:55AM	IQVIA Holdings Inc. (IQV): A Bull Case Theory (Insider Monkey)
Aug-22-25 08:29AM	What Are Wall Street Analysts' Target Price for IQVIA Holdings Stock? (Barchart)
Aug-21-25 11:30AM	IQVIA (IQV) Down 1.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-18-25 11:31PM	Q2 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks (StockStory)
09:00AM	IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes (Business Wire)
Aug-14-25 09:40AM	Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term (Zacks)
02:42AM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
Aug-13-25 10:57AM	UMAC Gears Up to Report Q2 Earnings: What's in the Offing? (Zacks)
Aug-11-25 09:50AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
05:19AM	Kexing Biopharm Enters Strategic Partnership with IQVIA to Accelerate Global Expansion (PR Newswire)
Aug-06-25 06:42PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
12:24PM	Avis Budget Stock Declines 22% Since Reporting Q2 Earnings Miss (Zacks)
Aug-05-25 12:23PM	Gartner Earnings Surpass Estimates in Q2, Revenues Increase Y/Y (Zacks)
Jul-30-25 10:42AM	Verisk Earnings & Revenues Surpass Estimates in Q2, Increase Y/Y (Zacks)
Jul-29-25 12:44PM	WM Earnings & Revenues Beat Estimates in Q2, Increase Y/Y (Zacks)
12:41PM	Fiserv Q2 Earnings Beat Estimates on Strong Margins, Revenues Miss (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
01:34AM	5 Revealing Analyst Questions From IQVIA's Q2 Earnings Call (StockStory)
Jul-28-25 10:45AM	IQVIA (IQV) Reliance on International Sales: What Investors Need to Know (Zacks)
Jul-24-25 06:37PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research)
11:17AM	Veeva's Vault Vision: Can It Thrive After Parting With Salesforce? (Zacks)
Jul-23-25 02:23PM	IQVIA Holdings (IQV) Snaps 2-Day Losses on Higher-than-Expected Earnings (Insider Monkey)
01:31PM	Why IQVIA (IQV) Stock Is Up Today (StockStory)
09:58AM	Fiserv's Q2 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
08:37AM	Stock Market News for Jul 23, 2025 (Zacks)
03:08AM	IQVIA Holdings Inc (IQV) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic AI ... (GuruFocus.com)
01:32AM	IQV Q2 Deep Dive: AI Initiatives and Pipeline Growth Drive Outperformance Amid Margin Pressures (StockStory)
Jul-22-25 05:55PM	Analyst Report: IQVIA Holdings Inc. (Morningstar Research) +17.88%
04:38PM	S&P 500 Gains & Losses Today: Homebuilder Stocks Soar; Lockheed Martin Loses Altitude (Investopedia)
04:06PM	Medpace Surges 55% On 'Shockingly Strong' Report; Pulling Iqvia Higher (Investor's Business Daily)
02:53PM	IQVIA Leads S&P 500 Gainers on Better-Than-Expected Earnings (Investopedia)
12:23PM	Top Stock Movers Now: GM, Lockheed Martin, IQVIA, DR Horton, and More (Investopedia)
12:15PM	IQVIA Earnings & Revenues Beat Estimates in Q2, Rise Y/Y (Zacks)
11:55AM	Why IQVIA (IQV) Stock Is Trading Up Today (StockStory)
09:08AM	Iqvia Surges As 'Pluses' Outweigh 'Minuses' In Its Second-Quarter Report (Investor's Business Daily)
08:15AM	IQVIA Holdings (IQV) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:37AM	IQVIA (NYSE:IQV) Beats Q2 Sales Targets, Stock Soars (StockStory)
07:16AM	IQVIA: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	IQVIA Reports Second-Quarter 2025 Results (Business Wire)
Jul-20-25 11:02PM	IQVIA Earnings: What To Look For From IQV (StockStory)
Jul-17-25 09:15AM	Countdown to IQVIA (IQV) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:52AM	What Makes IQVIA Holdings (IQV) an Investment Bet? (Insider Monkey)
08:08AM	Is IQVIA Holdings (IQV) an Attractive Investment Opportunity? (Insider Monkey)
Jul-16-25 10:00AM	Analysts Estimate Thermo Fisher Scientific (TMO) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:42AM	IQVIA Gears Up to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Jul-15-25 05:06PM	Top Stock Reports for Amazon.com, Meta Platforms & Shopify (Zacks)
10:00AM	IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? (Zacks)
12:05AM	3 Reasons IQV is Risky and 1 Stock to Buy Instead (StockStory)
Jul-11-25 09:45AM	Why IQVIA Holdings (IQV) is a Top Growth Stock for the Long-Term (Zacks)
Jul-10-25 11:40AM	IQVIA Unveils New Custom AI Agents with NVIDIA (Insider Monkey)
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Jul-09-25 11:52AM	Veeva Expands Market Reach Through Targeted Strategic Partnerships (Zacks)
Jul-08-25 12:05PM	VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait? (Zacks)
09:34AM	Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning (PR Newswire)
05:08AM	What to Expect From IQVIA Holdings' Q2 2025 Earnings Report (Barchart)
Jul-02-25 10:05AM	VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation (Zacks)
Jul-01-25 07:00AM	IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025 (Business Wire)
Jun-30-25 12:39AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-26-25 06:01PM	The Top 5 Analyst Questions From IQVIA's Q1 Earnings Call (StockStory)
10:15AM	Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. (Investor's Business Daily)
Jun-17-25 10:18AM	AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals, and Providers (PR Newswire)
Jun-16-25 11:34PM	Drug Development Inputs & Services Stocks Q1 Highlights: IQVIA (NYSE:IQV) (StockStory)
09:00AM	IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for 'Best Mobile App for Patient Engagement' (Business Wire)
Jun-11-25 07:00AM	IQVIA Launches New AI Agents for Life Sciences and Healthcare (Business Wire)

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARI BOUSBIB	Officer	Oct 29 '25	Proposed Sale	220.33	56,557	12,460,983		Oct 29 04:18 PM
ERIC SHERBET	Officer	Oct 29 '25	Proposed Sale	219.70	4,000	878,820		Oct 29 04:10 PM
Cherofsky Keriann	See Remarks	Jul 23 '25	Sale	191.53	549	105,150	2,910	Jul 25 05:01 PM
Sherbet Eric	See Remarks	Jul 23 '25	Option Exercise	97.20	11,870	1,153,764	32,978	Jul 25 05:00 PM
Sherbet Eric	See Remarks	Jul 23 '25	Sale	190.05	5,800	1,102,290	27,178	Jul 25 05:00 PM
ERIC SHERBET	Officer	Jul 23 '25	Proposed Sale	190.05	5,800	1,102,262		Jul 23 05:53 PM
KERIANN CHEROFSKY	Officer	Jul 23 '25	Proposed Sale	191.53	549	105,150		Jul 23 04:01 PM
BOUSBIB ARI	See Remarks	Feb 10 '25	Option Exercise	65.16	40,000	2,606,400	837,083	Feb 12 05:11 PM
DANHAKL JOHN G	Director	Dec 03 '24	Buy	200.58	1,275	255,740	1,275	Feb 07 07:03 PM

Open in Screener

OABI

OmniAb Inc

Oct 30 • 04:00PM ET

1.49

+0.02 1.36 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: VTI IWM VXF IWN SCHA VTWO VHT DFAT IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	28.76%	Shs Outstand	122.70M	Perf Week	-6.88%
Market Cap	214.49M	Forward P/E	-	EPS next Y	-0.42	Insider Trans	0.29%	Shs Float	102.56M	Perf Month	-7.45%
Enterprise Value	194.65M	PEG	-	EPS next Q	-0.14	Inst Own	38.07%	Short Float	5.83%	Perf Quarter	-21.99%
Income	-63.52M	P/S	9.31	EPS this Y	4.92%	Inst Trans	-12.95%	Short Ratio	12.07	Perf Half Y	-15.82%
Sales	23.03M	P/B	0.70	EPS next Y	27.87%	ROA	-20.07%	Short Interest	5.98M	Perf YTD	-57.91%
Book/sh	2.14	P/C	5.15	EPS next 5Y	18.52%	ROE	-22.84%	52W High	4.87 -69.40%	Perf Year	-61.50%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-22.68%	52W Low	1.22 22.13%	Perf 3Y	-83.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	15.37%	Volatility	6.13% 6.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	8.45	EPS Y/Y TTM	2.24%	Oper. Margin	-301.33%	ATR (14)	0.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.77	Sales Y/Y TTM	6.05%	Profit Margin	-275.83%	RSI (14)	38.83	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.77	EPS Q/Q	-11.31%	SMA20	-9.19%	Beta	0.16	Target Price	8.50
Payout	-	Debt/Eq	0.08	Sales Q/Q	-48.82%	SMA50	-8.62%	Rel Volume	5.97	Prev Close	1.47
Employees	114	LT Debt/Eq	0.07	Earnings	Nov 04 AMC	SMA200	-29.88%	Avg Volume	495.21K	Price	1.49
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.81% -26.94%	Trades		Volume	2,956,383	Change	1.36%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
08:00AM	Loading…
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	Loading…
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
08:00AM	Loading…
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM
Berkman Charles S	Chief Legal Officer	Jan 21 '25	Sale	3.24	25,489	82,584	343,190	Jan 22 05:41 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Jan 21 '25	Sale	3.24	15,526	50,304	212,720	Jan 22 05:40 PM
FOEHR MATTHEW W	President and CEO	Jan 21 '25	Sale	3.24	41,811	135,468	3,749,639	Jan 22 05:40 PM
FOEHR MATTHEW W	Officer	Jan 21 '25	Proposed Sale	3.24	41,811	135,378		Jan 21 07:25 PM
Berkman Charles S	Officer	Jan 21 '25	Proposed Sale	3.24	25,489	82,529		Jan 21 07:24 PM
GUSTAFSON KURT A	Officer	Jan 21 '25	Proposed Sale	3.24	15,526	50,271		Jan 21 07:22 PM
Berkman Charles S	Chief Legal Officer	Dec 09 '24	Sale	4.13	8,022	33,131	323,385	Dec 10 04:47 PM
FOEHR MATTHEW W	President and CEO	Dec 09 '24	Sale	4.13	13,634	56,308	3,714,447	Dec 10 04:44 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 09 '24	Sale	4.13	23,871	98,587	200,661	Dec 10 04:41 PM
GUSTAFSON KURT A	Officer	Dec 09 '24	Proposed Sale	4.13	23,871	98,476		Dec 09 08:49 PM
FOEHR MATTHEW W	Officer	Dec 09 '24	Proposed Sale	4.13	13,634	56,245		Dec 09 08:45 PM
Berkman Charles S	Officer	Dec 09 '24	Proposed Sale	4.13	8,022	33,094		Dec 09 08:41 PM
FOEHR MATTHEW W	President and CEO	Nov 25 '24	Option Exercise	3.73	99,434	370,702	3,698,600	Nov 26 04:41 PM

MEDP

INCY

NOTV

ABSI

MXCT

CRL

NRC

IQV

OABI

Upgrade your FINVIZ experience